Document:

__________________________________________________

ASSET
PURCHASE AGREEMENT

__________________________________________________

 

dated
as of March 18, 2016

between

MIGRALEX,
INC.

and

EMBER
THERAPEUTICS, INC.

    	 	1	 

    	 	 	 

    

ASSET
PURCHASE AGREEMENT

This
ASSET PURCHASE AGREEMENT (this “Agreement”), is made and entered into as of March 18,
2016 (the “Agreement Date”), by and among Migralex, Inc., a Delaware Corporation (“Seller”),
and Ember Therapeutics, Inc., a Delaware corporation (“Purchaser”).

R
E C I T A L S

Seller
desires to sell and assign to Purchaser, and Purchaser desires to purchase and acquire from Seller (as provided herein), all assets,
patents, trademarks, including Dr. Mauskop’s trademark, formulation, proposed formulations, contracts, working inventory,
marketing material, websites, licenses and certain other assets of the Business currently owned by Seller on the terms and conditions
set forth in this Agreement.

NOW,
THEREFORE, in consideration of the facts recited above and the mutual agreements set forth herein, the parties hereby agree as
follows:

ARTICLE
I

DEFINITIONS

Section
1.01                    Certain
Defined Terms. As used in this Agreement, the following terms will have the following meanings:

“Accounts
Receivable” means all accounts receivable of the Seller attributable to the Business.

“affiliate”
means, with respect to any specified Person, any other Person that directly or indirectly controls, is controlled by,
or is under common control with, such specified Person.

“Ancillary
Agreement” will have the meaning set forth in Section 3.01.

“AR
Schedules” will have the meaning set forth in Section 3.05.

“Assigned
Contract” will have the meaning set forth in Section 2.02(g).

“Assumed
Liabilities” will have the meaning set forth in Section 2.04(a).

“Bill
of Sale” will have the meaning set forth in Section 2.10(a).

“Business”
means Seller’s business of manufacturing and marketing Migralex, an OTC pain medication and developing, marketing,
licensing, distributing or otherwise commercially exploiting, all or any aspect of the product, the Intellectual Property Rights
and/or any aspect or part thereof.

    	 	2	 

    	 	 	 

    

“Business
Contract” shall mean any Contract relating to the Business: (a) to which the Seller is a party; (b) by
which the Seller or any of its assets is bound or under which the Seller has any obligation; or (c) under which the Seller
has any right or interest.

“Business
Records” will have the meaning set forth in Section 2.02(h).

“Business
Tangible Assets” will have the meaning set forth in Section 2.02(f).

“Closing”
and “Closing Date” will have the respective meanings specified for such terms in Section 2.07.

“Closing
Date Balance Sheet” will have the meaning set forth in Section 7.02(c).

“COBRA”
will have the meaning set forth in Section 2.04(ix).

“Confidential
Information” will have the meaning set forth in Section 5.03.

“Contract”
shall mean any binding written, oral, implied or other agreement, contract, understanding, arrangement, instrument, note, guaranty,
indemnity, deed, assignment, power of attorney, certificate, purchase order, work order, insurance policy, benefit plan or commitment.

“control”
(including the terms “controlled by” and “under common control with”)
means the possession, directly or indirectly, of the power to direct or cause the direction of the management policies of a Person,
whether through the ownership of stock, as an officer, director, trustee or executor, by contract or otherwise.

“Disclosing
Party” will have the meaning set forth in Section 5.03.

“Documentation”
means, collectively customer accounts, all programmers’ notes or logs, source code annotations, user guides, manuals,
instructions, software architecture designs, layouts, any know-how, and any other designs, plans, drawings, documentation or materials
that are related in any manner to any Intellectual Property Rights, whether in tangible or intangible form.

“Domain
Transfer Agreements” will have the meaning set forth in Section 2.10(d).

“Encumbrance”
means any pledge, lien, collateral assignment, security interest, mortgage, title retention, conditional sale or other
security arrangement, or any charge, adverse claim of title, ownership or right to use, or any other encumbrance of any kind whatsoever.

“ERISA”
will have the meaning set forth in Section 2.04(ix).

“Excluded
Assets” will have the meaning set forth in Section 2.03.

“Excluded
Liabilities” will have the meaning set forth in Section 2.04(a).

“Gross
Margin” will have the meaning set forth in Section 2.06(c).

    	 	3	 

    	 	 	 

    

“Indemnified
Party and Indemnifying Party” will have the meaning set forth in Section 9.04.

“Intellectual
Property Rights” means, collectively, all of the following intangible worldwide legal rights of the Seller
with respect to the Business, whether or not filed, perfected, registered or recorded: (i) patents, patent applications, and patent
rights, including any and all continuations, continuations-in-part, divisions, reissues, reexaminations or extensions thereof,
whether now existing or hereafter filed, issued or acquired; (ii) rights associated with works of authorship (including audiovisual
works), including copyrights, copyright applications, and copyright registrations, moral rights; (iii) rights relating to the
protection of trade secrets and confidential information; (iv) design rights and industrial property rights; (v) any rights analogous
to those set forth in the preceding clauses and any other proprietary rights relating to intangible property including trademarks,
service marks, trademark and service mark registrations and applications therefor, trade names, rights in trade dress and packaging
and all goodwill associated with the same; (vi) rights in customer and prospect lists, trade secrets, know-how, designs, plans
and specifications; and (vii) all rights to sue for any past, present or future infringement of any of the foregoing rights and
the right to all income, royalties, damages and payments now or hereafter due or payable with respect to any of the foregoing
rights, including without limitation damages for past, present or future infringement thereof. The term “Intellectual Property
Rights” does not refer to tangibles or tangible embodiments of Intellectual Property Rights.

“Internal
Revenue Code” means the Internal Revenue Code of 1986, as amended, and the rulings and regulations promulgated
thereunder.

“JAMS”
will have the meaning set forth in Section 11.01.

“Liabilities”
means any and all debts, liabilities and obligations, whether accrued or fixed, absolute or contingent, matured or unmatured,
determined or determinable, known or unknown, including, without limitation, those arising under any law, action or governmental
order and those arising under any contract, agreement, arrangement, commitment or undertaking.

“Loss”
will have the meaning set forth in Section 9.01.

“Patent
Assignment” will have the meaning set forth in Section 2.10(d). 

“Person”
means any individual, partnership, firm, corporation, association, trust, unincorporated organization or other entity.

“Purchased
Assets” will have the meaning set forth in Section 2.02.

“Purchase
Price” will have the meaning set forth in Section 2.05(a).

“Purchaser
Indemnitees” will have the meaning set forth in Section 9.01.

“Receiving
Party” will have the meaning set forth in Section 5.03.

    	 	4	 

    	 	 	 

    

“Seller’s
Confidential Information” will have the meaning set forth in Section 5.03(b).

“Seller
Indemnitees” will have the meaning set forth in Section 9.01.

“Straddle
Periods” will have the meaning set forth in Section 6.02.

“Tax”
or “Taxes” means all foreign, federal, state and local taxes of any kind whatsoever (whether
payable directly or by withholding), including but not limited to sales, use, excise, franchise, ad valorem, property, inventory,
value added and payroll taxes, together with any interest and penalties, additions to tax or additional amounts with respect thereto,
imposed by any taxing authority.

“Termination
Date” will have the meaning set forth in Section 10.01(b).

“Third-Party
Claim” will have the meaning set forth in Section 9.03.

“Transaction
Taxes” will have the meaning set forth in Section 6.01.

“WARN”
will have the meaning set forth in Section 2.04(ix).

ARTICLE
II

PURCHASE AND SALE OF PURCHASED ASSETS

Section
2.01                    Agreement
to Sell and Purchase. Subject to the terms and conditions of this Agreement, on the Closing Date, Seller will sell, assign,
transfer, convey and deliver to Purchaser, and Purchaser will purchase and acquire, all right, title and interest in and to the
Purchased Assets (as defined below) free and clear of all Encumbrances whatsoever.

Section
2.02                    Purchased
Assets Defined. As used in this Agreement, the term “Purchased Assets” will mean, collectively,
each and all of Seller’s right, title and interest in, to and under the following assets and properties of the Business:

(a)               
the current inventory and pending orders of finished goods, including finished goods, work in process, raw materials, packaging
materials, current and future formulations, current in store credits, store inventory and related material;

(b)              
the toll free number that is exclusively related to the Business, any software and associated hardware used to operate the ordering
and customer support software of the Business;

(c)               
the Documentation, Website and Domain Names;

(d)              
the Intellectual Property Rights;

(e)               
the Accounts Receivable and vendor credits;

    	 	5	 

    	 	 	 

    

(f)               
any and all copies in a tangible medium and other tangible embodiments of (i) the Documentation; and (ii) the Intellectual Property
Rights;

(g)              
(i) all documentation, marketing materials, promotional literature, videos, commercials, images and other sales or marketing-related
materials and other collateral information used in connection with the Business as of March 1, 2016; and (ii) any computer equipment
used for the Business together with all software installed on such computer equipment (collectively, the “Business
Tangible Assets”);

(h)              
those Business Contracts listed on Exhibit A attached hereto (collectively hereinafter referred to as the “Assigned
Contracts”); and

(i)                
all of Seller’s marketing and sales information, including customer pricing, marketing plans, business plans, financial
and business projections, customer lists, customer relationship management and sales tracking software and data and all other
files and records (or applicable portions thereof) pertaining to the Business (the “Business Records”),
it being understood that Seller may retain the copies of such Business Records.

Section
2.03                    Excluded
Assets. As used herein, the term “Excluded Assets” means any asset or property of Seller not expressly
included among the Purchased Assets. Purchaser is not purchasing any of the Excluded Assets.

Section
2.04                    Assumption
and Exclusion of Liabilities.

(a)               
Assumed Liabilities. Subject to the terms and conditions of this Agreement, Purchaser, upon the successful consummation
of the sale and purchase of the Purchased Assets pursuant hereto on the Closing Date, will assume and pay, perform and discharge
when due any and all Liabilities of Seller arising out of or related to the Business or the Purchased Assets on or after the Closing
other than the Excluded Liabilities (as defined below), including, without limitation, (i) all Liabilities under the Assigned
Contracts arising on or after the Closing Date (other than any obligations and liabilities that arise from any breach, violation
or default by Seller of the terms of the Assigned Contracts), (ii) all Liabilities for Taxes with respect to the Purchased Assets
that arise after the Closing Date and (iii) all account payables incurred or accruing from and after the Closing (collectively,
the “Assumed Liabilities”).

(b)              
No Other Liabilities Assumed. As a material consideration and inducement to Purchaser to enter into this Agreement, Seller
will retain, and will be solely responsible for paying, performing and discharging when due, and Purchaser will not assume or
otherwise have any responsibility or liability for, any and all Liabilities of Seller (whether now existing or hereafter arising)
other than the Assumed Liabilities (the “Excluded Liabilities”). By way of example and not by
way of limitation, the Excluded Liabilities that are not being assumed by Purchaser include, without limitation;

(i)                
any and all Taxes now or hereafter due and payable by Seller or any affiliate of Seller (including without limitation any Taxes
that Seller agrees to pay pursuant to ARTICLE VI hereof);

    	 	6	 

    	 	 	 

    

(ii)              
any and all Taxes attributable to any of the Purchased Assets that arose during any time period or portion thereof ending on or
prior to the Closing Date;

(iii)            
any and all Taxes attributable to the Seller whenever such Taxes arose;

(iv)            
any and all trade payables incurred or accrued by the Seller at any time prior to the Closing Date;

(v)              
any and all Liabilities with respect to any environmental damage, or for any disposal, discharge or other use or treatment of
any hazardous or toxic substance, under any and all laws and regulations relating to the environment or the regulation of any
hazardous or toxic substances of any type (other than such Liabilities arising under Purchaser’s operation of the Business
or the Purchased Assets);

(vi)            
any and all Liabilities to the Seller’s employees or contractors related to or arising from or with respect to any act or
omission of Seller or arising from or with respect to any event, including without limitation any Liabilities to any of the Seller’s
employees for the payment of any and all wages and commissions or accrued and unused vacation time or for the reimbursement of
any expenses incurred by Seller’s employees and any Liabilities to any of the Seller’s contractors for any amounts
due to them in connection with services provided to Seller;

(vii)          
any and all Liabilities arising from the termination by Seller of the employment of any current or future employees of Seller
or any of its affiliates, any other claims brought against Seller arising from Seller’s employment of any person, or arising
from any duties or obligations under any existing or future employee benefit plans of Seller or any of its affiliates;

(viii)        
any and all Liabilities with respect to Taxes arising from Seller’s use of contractors in connection with the Business;

(ix)            
any and all present or future obligations or Liabilities of Seller or any of its affiliates to existing or future employees of
Seller or any of its affiliates under the Employee Retirement Income Security Act of 1974, as amended, and the rulings and regulations
promulgated thereunder (“ERISA”), the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended
(“COBRA”), the Federal Worker Adjustment and Retraining Act (“WARN”) or any
severance pay obligations of Seller or any of its affiliates;

(x)              
any and all Liabilities arising from any breach or default by Seller of any contract, agreement or commitment of Seller (including
but not limited to any breach or default of any of the Assigned Contracts);

(xi)            
any and all Liabilities now or hereafter arising from or with respect to, the sale or license of any products or services of,
by or for Seller (other than, for the avoidance of doubt, the Assumed Liabilities);

(xii)          
any and all Liabilities relating to or arising out of any of the Excluded Assets; and

(xiii)        
any and all inter-company payables incurred by, or owed to, the Business accrued or arising prior to the Closing Date.

Section
2.05                    

    	 	7	 

    	 	 	 

    

Purchase
Price; Royalty; and Development and Commercialization.

(a)               
Purchase Price. The aggregate purchase price for the Purchased Assets to be paid by Purchaser (the “Purchase
Price”) will be in Common Stock and in Warrants in the manner and according to the following;

(i)                
 the issuance of one million five hundred seventy eight thousand nine hundred forty eight (1,578,948) shares of Ember common stock
(the “Common Stock) ; and

(ii)              
the issuance of warrants (the “Warrants”) to purchase five hundred twenty six thousand three hundred
and sixteen (526,316) shares of Common Stock at an exercise price per Warrant equal to $0.95 and having a five (5) year expiration
date from the Closing Date.

(b)              
Royalty. Purchaser shall pay Dr. Mauskop a *** (***) fee on all Migralex and related products sales for the first
three (3) years after Closing on the terms and conditions as set forth under the Consulting Agreement (as defined below). This
payment shall be made on a yearly basis as set forth thereunder.

(c)               
Development & Commercialization. Purchaser shall use its reasonable commercial diligence in developing and commercializing
Migralex’s technologies. Subject to Seller’s rights pursuant to Section 8.06, Ember will invest at least five million
dollars ($5,000,000) in sales and marketing and product line extension during the twelve (12) month period following the Closing.

Section
2.06                    Right
of Set-Off. Purchaser’s obligation to make payments to Seller pursuant to 2.05 or Section 2.08 shall be subject to reduction
or non-payment by an amount equal to the amount of any Losses for which the parties have agreed that Purchaser is entitled to
indemnification pursuant to ARTICLE IX, it being understood that the parties shall in good faith pursue
resolution of any such indemnification claims made by Purchaser.

Section
2.07                    Closing.
Subject to the terms and conditions of this Agreement, the sale and purchase of the Purchased Assets contemplated hereby will
take place at a closing 135 East 57th Street, 24th Floor, NY, NY 10022 (the “Closing”)
at 9:00 a.m., Eastern Time, after the satisfaction or waiver of the conditions to Closing set forth in ARTICLE VII or at such
other time or on such other date on or before March 31, 2016 or at such other place (or by such other means, including a remote
Closing wherein the relevant documents are delivered by means of facsimile, mail or courier) as Seller and Purchaser may mutually
agree (the day on which the Closing takes place being referred to herein as the “Closing Date”).

Section
2.08                    Certain
Closing Deliveries by Seller. At the Closing (in addition to Seller’s delivery of the items, documents and certificates
to be delivered by Seller at the Closing pursuant to Section 7.02), Seller will deliver or cause to be delivered to Purchaser
all of the following items, against delivery to Seller of the items, payments, documents and certificates to be delivered to Seller
by Purchaser at the Closing pursuant to Section 2.09 and Section 7.01 hereof:

    	 	8	 

    	 	 	 

    

(a)               
counterparts of the Bill of Sale (the “Bill of Sale”) and Assignment and Assumption Agreement (the “Assumption
Agreement”) in substantially the form of Exhibit B attached hereto executed by a duly authorized officer
of Seller;

(b)              
fully executed Consulting Agreement with Dr. Mauskop whose tasks shall include promoting the transaction and the commercial efforts
of the product, including, but not limited to interviews, guest appearances, commercial participation and speaker engagements.
Dr. Mauskop shall be paid an hourly fee of two hundred and fifty ($250) per hour and a minimum monthly consulting fee of $5,000.
Exhibit C attached hereto (the “Consulting Agreement”);

(c)               
a receipt for the Purchase Price executed by a duly authorized officer of Seller;

(d)              
assignments from Seller to Purchaser of all patent rights included in the Purchased Assets and all registered and unregistered
trademarks and service marks included in the Purchased Assets, duly executed on behalf of Seller by a duly authorized officer
of Seller, and in a form acceptable for recording with the United States Patent and Trademark Office, and in substantially the
form of Exhibit D attached hereto (the “Patent Assignment”) or Exhibit E attached
hereto (the “Mark Assignment”), as applicable; and

(e)               
fully executed domain name transfer agreements (the “Domain Transfer Agreements”) for each of the domain
names included in the Purchased Assets in the form of Exhibit F.

Section
2.09                    Certain
Closing Deliveries by Purchaser. At the Closing (in addition to Purchaser’s delivery of the items, documents and certificates
to be delivered by Purchaser at the Closing pursuant to Section 7.01), Purchaser will deliver to Seller all of the following
items, against delivery to Purchaser of the items, documents, assets and certificates to be delivered to Purchaser by Seller at
the Closing pursuant to Section 2.08 and Section 7.02 hereof:

(a)               
the Purchase Price (as evidenced by certificates for the Common Stock and the Warrants); and

(b)              
counterparts of the Assumption Agreement, executed on behalf of Purchaser by duly authorized representatives of Purchaser.

ARTICLE
III

REPRESENTATIONS AND WARRANTIES OF SELLER

Seller
hereby represents and warrants to the best knowledge of the Seller to Purchaser that, except as may be expressly otherwise set
forth in Seller’s Disclosure Schedule attached as Exhibit K hereto, all of the following statements in this
ARTICLE III are true and correct:

Section
3.01                    Incorporation
and Authority. Seller is a corporation duly incorporated, validly existing and in good standing under the laws of the State
of Delaware and has all necessary corporate power and authority to enter into this Agreement, the Bill of Sale and the Assumption
Agreement (the Bill of Sale and the Assumption Agreement, together with all other

    	 	9	 

    	 	 	 

    

assignments
and documents that Seller is to execute and deliver pursuant to this Agreement being hereinafter collectively referred to as the
“Ancillary Agreements”), to carry out and perform its obligations hereunder and thereunder and to consummate
all of the transactions contemplated hereby and thereby. The execution, delivery and performance by Seller of this Agreement and
the Ancillary Agreements, and the sale of the Purchased Assets to Purchaser and consummation of all the transactions contemplated
hereby and thereby on the terms and conditions set forth herein, have been duly and validly authorized by Seller by all necessary
corporate action of Seller’s Board of Directors and shareholders. No authorization, decree or order of any court, bankruptcy
court, bankruptcy trustee, creditors’ committee, receiver, governmental authority or any other person is required in order
to authorize or enable Seller to: (i) enter into this Agreement and the Ancillary Agreements; (ii) sell, assign, convey and transfer
all the Purchased Assets to Purchaser as contemplated by this Agreement; or (iii) to carry out and perform Seller’s obligations
under this Agreement and the Ancillary Agreements. This Agreement has been, and at the Closing the Ancillary Agreements will be,
duly and validly executed and delivered by Seller, and (assuming due authorization, execution and delivery by Purchaser) this
Agreement constitutes and, upon the execution of each of the Ancillary Agreements by the parties thereto, the Ancillary Agreements
will constitute, legal, valid and binding obligations of Seller enforceable against Seller in accordance with their respective
terms.

Section
3.02                    No Conflict.
The execution, delivery and performance of this Agreement and the Ancillary Agreements by Seller, do not and will not: (i) conflict
with or violate the Certificate of Incorporation or By-laws of Seller; (ii) conflict with or violate any law, rule, regulation,
order, writ, judgment, injunction, decree, determination or award applicable to the Purchased Assets; (iii) result in any material
breach of, or constitute a default (or event which with the giving of notice or lapse of time, or both, would become a default)
under, or give to others any rights of termination, rescission, amendment, acceleration or cancellation of, any of the Assigned
Agreements or any material note, bond, mortgage, indenture, contract, agreement, lease, license, permit, franchise or other instrument
relating to any of the Purchased Assets to which Seller is a party or is bound or by which any of the Purchased Assets are bound
or affected; or (iv) result in the creation of any Encumbrance on any of the Purchased Assets.

Section
3.03                    Consents
and Approvals. Except as set forth on Schedule 3.03 of Seller’s Disclosure Schedule, the execution and delivery
of this Agreement and the Ancillary Agreements by Seller do not, and the performance of this Agreement and the Ancillary Agreements
by Seller (including Seller’s assignment of any Assigned Contracts to Purchaser) will not, require any material consent,
approval, authorization or other action by, or filing with or notification to, any third party, including but not limited to any
governmental or regulatory authority.

Section
3.04                    Title
to and Condition of Purchased Assets. Seller owns all the Purchased Assets and Seller has good and marketable title in and
to all the Purchased Assets, free and clear of all Encumbrances whatsoever. None of the Purchased Assets is licensed from any
third party and none of the Purchased Assets is licensed to any third party. All of the tangible personal property included in
the Purchased Assets is conveyed in an “as is” condition. Title to all the Purchased Assets is freely transferable
from Seller to Purchaser free and clear of all Encumbrances without obtaining the consent or approval of any person or party.

Section
3.05                    

    	 	10	 

    	 	 	 

    

Accounts
Receivable. The Accounts Receivable are not subject to any factoring agreement or similar arrangement. A schedule of the Accounts
Receivable as of the Agreement Date are set forth in Schedule 3.05 of the Seller’s Disclosure Schedule (the “AR
Schedule”). The AR Schedule is accurate and complete and all of the Accounts Receivable set forth on the AR Schedule
are conveyed in an “as is” condition.

Section
3.06                    Full
Force and Effect. Each Assigned Contract, permit, franchise or other instrument assigned to or assumed by Purchaser pursuant
to this Agreement or any of the Ancillary Agreements is in full force and is not subject to any breach or default of any material
term thereunder by any party thereto.

Section
3.07                    Litigation.
There is no claim, action, suit, investigation or proceeding of any nature pending or, to the best of Seller’s knowledge,
threatened, at law or in equity, by way of arbitration or before any court, governmental department, commission, board or agency
that: (i) may adversely affect, contest or challenge Seller’s authority, right or ability to sell or convey any of the Purchased
Assets to Purchaser hereunder or otherwise perform Seller’s obligations under this Agreement or any of the Ancillary Agreements;
(ii) challenges or contests Seller’s right, title or ownership of any of the Purchased Assets; (iii) asserts that any Purchased
Asset, or any action taken by any employee or agent of the Seller with respect to any Purchased Asset, infringes any Intellectual
Property Rights of any third party or constitutes a misappropriation or misuse of any Intellectual Property Rights, trade secrets
or proprietary rights of any party; (iv) seeks to enjoin, prevent or hinder the consummation of any of the transactions contemplated
by this Agreement or the Ancillary Agreements; (v) would impair or have an adverse affect on Purchaser’s right or ability
to use or exploit any of the Purchased Assets or impair or have an adverse effect on the value of any Purchased Asset; or (vi)
involves a wrongful termination, harassment or other employment-related claim by any employee, potential employee or contractor
of Seller. There are no judgments, decrees, injunctions or orders of any court, governmental department, commission, agency, instrumentality
or arbitrator pending or binding against Seller which affect the Purchased Assets.

Section
3.08                    Tax
Matters.

(a)               
Except as set forth in Schedule 3.08 of Seller’s Disclosure Schedule, each Tax required to have been paid, or claimed
by any person to be payable, by the Seller has been duly paid in full on a timely basis. Any Tax required to have been withheld
or collected by the Seller has been duly withheld and collected; and (to the extent required) each such Tax has been paid to the
appropriate person.

(b)              
Schedule 3.08 of the Seller’s Disclosure Schedule accurately identifies each examination or audit of any tax return
of the Seller that has been conducted since December 31, 2013. The Seller has delivered to the Purchaser accurate and complete
copies of all audit reports and similar documents (to which the Seller has access) relating to such tax returns.

(c)               
Except as set forth in Schedule 3.08 of the Seller’s Disclosure Schedule, no claim or other proceeding is pending
or has been threatened against or with respect to the Seller in respect of any Tax. There are no unsatisfied Liabilities for Taxes
(including liabilities for interest, additions to tax and penalties thereon and related expenses) with respect to any notice of

    	 	11	 

    	 	 	 

    

deficiency
or similar document received by the Seller. The Seller has not entered into or become bound by any agreement or consent pursuant
to Section 341(f) of the Internal Revenue Code.

(d)              
The Seller has delivered to (or made available for inspection by) the Purchaser accurate and complete copies of all tax returns
that have been filed on behalf of or with respect to the Seller. The information contained in such tax returns is accurate and
complete in all respects.

Section
3.09                    Employees
and Employment Taxes. Seller is not a party to or bound by any union contract and has not experienced any strike, grievance
or any arbitration proceeding, claim of unfair labor practices filed or, to the best of Seller’s knowledge, threatened to
be filed or any other material labor difficulty. To the best of Seller’s knowledge, no organizational effort is being or
has been made or threatened by or on behalf of any labor union with respect to any employees. Seller has withheld all federal
and state income Taxes, FICA, FUTA and other Taxes required to be withheld and paid such withheld amounts to the appropriate governmental
body within the time period prescribed by law.

Section
3.10                    Compliance
with Laws. Seller has complied in all material respects with, and has not received any notices of violation with respect to,
any federal, state or local statute, law or regulation (including but not limited to environmental laws), domestic or foreign,
applicable to the Business, Seller’s conduct of the Business or any of the Purchased Assets, including without limitation
(i) all applicable Tax laws and regulations with respect to consultants, (ii) the Export Administration Act and regulations promulgated
thereunder and all other laws, regulations, rules, orders, writs, injunctions, judgments and decrees applicable to the export
or re-export of controlled commodities or technical data and (iii) the Immigration Reform and Control Act.

Section
3.11                    Intellectual
Property.

(a)               
The Purchased Assets include all Intellectual Property Rights necessary to enable Purchaser to conduct the Business in substantially
the same manner in which such business was conducted on March 1st, 2016, without the need for any license from any
person.

(b)              
The Purchased Assets and the distribution, sale and license of such Purchased Assets, including but not limited to the Documentation
and, the Intellectual Property Rights do not infringe upon any Intellectual Property Rights of any third party and no third party
has asserted or threatened to assert against Seller any claim of infringement of Intellectual Property Rights.

(c)               
Seller owns, possesses, has the exclusive right to make, use, sell, license, has the right to bring actions for the infringement
of, and where necessary, has made timely and proper applications for, the Intellectual Property Rights used in the Business that
are included in the Purchased Assets.

(d)              
Seller has not granted any third party any outstanding licenses or other rights to any of the Purchased Assets.

    	 	12	 

    	 	 	 

    

(e)               
None of the Purchased Assets is held or used pursuant to a license or similar grant of rights by any third party (other than “shrink-wrap”
and similar commercially available end-user licenses).

(f)               
Neither Seller nor any of its affiliates is liable for, nor has made any contract or arrangement whereby it may become liable
to, any person for any royalty, fee or other compensation for the ownership, use, license, sale, distribution, manufacture, reproduction
or disposition of any Purchased Asset.

(g)              
All employees and consultants of Seller and any other third parties who have been involved in the product development of Seller’s
Business or who were otherwise involved in the creation and/or development of the Documentation and/or the Intellectual Property
Rights have executed invention assignment agreements in the form delivered to Purchaser’s counsel and all employees and
consultants of Seller who have access to confidential information or trade secrets of the Business and/or which relate to Purchased
Assets have executed appropriate nondisclosure agreements in the form delivered to Purchaser’s counsel.

(h)              
Seller has taken reasonable steps, consistent with industry standards, to protect the secrecy and confidentiality of all Documentation
and Intellectual Property Rights.

Section
3.12                    Product
Warranties; Defects. Each product manufactured, sold, licensed, leased or delivered by the Seller in connection with
the Business has been in substantial conformity with all applicable contractual commitments and all express warranties made by
the Seller and there is, to the best of Seller’s knowledge, no basis for any present or future action, suit, proceeding,
hearing, investigation, charge, complaint, claim, or demand against any such contractual commitments or express warranties for
replacement or repair thereof or other damages in connection therewith. No product manufactured, sold, licensed, leased or delivered
by the Seller in connection with the Business is subject to any guaranty, warranty, or other indemnity beyond the Seller’s
applicable standard terms and conditions of sale, lease or licensing (as set forth in written agreements that Seller has delivered
to Purchaser) or beyond that imposed by applicable law.

Section
3.13                    Assigned
Contracts.

(a)               
Exhibit A identifies each Assigned Contract. The Seller has delivered to the Purchaser accurate and complete copies
of all Contracts identified in Exhibit A, including all amendments thereto. Each Contract is valid and in full force
and effect.

(b)              
Except as set forth in Schedule 3.13 of the Seller’s Disclosure Schedule: (i) no party has violated or breached,
or declared or committed any default under, any material provision of an Assigned Contract; (ii) no event has occurred, and no
circumstance or condition exists, that might (with or without notice or lapse of time) (A) result in a violation or breach
of any of the material provisions of any Assigned Contract, (B) give any party the right to declare a default or exercise
any remedy under any Assigned Contract, (C) give any party the right to accelerate the maturity or performance of any Assigned
Contract, or (D) give any party the right to cancel, terminate or modify any Assigned Contract; (iii) the Seller has not received
any notice or other communication (in writing or otherwise) regarding any actual, alleged, possible or

    	 	13	 

    	 	 	 

    

potential
violation or material breach of, or default under, any Assigned Contract; and (iv) the Seller has not waived any material right
under any Assigned Contract.

(c)               
Except as set forth in Schedule 3.13 of the Seller’s Disclosure Schedule, the Seller has not guaranteed or otherwise
agreed to cause, insure or become liable for, and the Seller has never pledged any of its assets to secure, the performance or
payment of any obligation or other Liability of any other party.

(d)              
No party is renegotiating, or has the right to renegotiate, any amount paid or payable to the Seller under any Assigned Contract
or any other material term or provision of any Assigned Contract.

(e)               
The Seller has no knowledge of any basis upon which any party to any Assigned Contract may object to (i) the assignment to
the Purchaser of any right under such Assigned Contract, or (ii) the delegation to or performance by the Purchaser of any
obligation under such Assigned Contract.

Section
3.14                    Government
Contracts. Seller is not, and has not been a party to any contract or arrangement with any foreign or U.S. federal, state
or local government agency relating to the Business other than those identified on Schedule 3.14 of Seller’s Disclosure
Schedule.

Section
3.15                    Oral
Contracts. Seller is not, and has not been a party to any material contract or arrangement that has not been set forth in
a written contract (a copy of which has been delivered by Seller to Purchaser).

Section
3.16                    Liabilities.

(a)               
Set forth on Schedule 3.16 of Seller’s Disclosure Schedule are all Liabilities of Seller that are fixed or determinable
or otherwise includable in a balance sheet presentation of liabilities of the Company prepared in a manner consistent with prior
periods and which materially represents the liabilities of the Company. There are no contingent liabilities of Seller except as
set forth on Schedule 3.16, except for obligations under the Assigned Contracts listed on Exhibit A, to the
extent that the existence of such obligations is ascertainable solely by reference to such Assigned Contracts.

(b)              
Schedule 3.16 of Seller’s Disclosure Schedule: (i) provides a breakdown of the accounts payable of the Seller; (ii)
provides a breakdown of any customer deposits or other deposits held by the Seller as of the date of this Agreement; and (iii)
provides a breakdown of all notes payable and other indebtedness of the Seller as of the date of this Agreement.

Section
3.17                    Fair
Value. Seller’s Board of Directors has determined in good faith that the Purchase Price represents the fair market value
of the Purchased Assets. No order has been made, no petition presented, or resolution passed for the winding-up of Seller, or
then appointment of any trustee or for the benefit of creditors or the preparation or commencement of any bankruptcy or insolvency
proceeding nor has any resolution been passed, agreement entered

    	 	14	 

    	 	 	 

    

into,
or term sheet or letter of intent approved by Seller with respect to a future sale or disposition of material assets of Seller
other than pursuant to this Agreement.

Section
3.18                    No Brokers.
Except for Inbar Group, Inc., no broker, finder or investment banker is entitled to any brokerage, finder’s or other fee
or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf
of Seller or its affiliates.

Section
3.19                    No Other
Representations and Warranties. Except for the representations and warranties expressly contained in this ARTICLE III
(as modified by the Seller’s Disclosure Schedule), neither Seller nor any other Person makes any other express or implied
(by statute or otherwise), representation or warranty with respect to Seller, the Purchased Assets, the Business or the transactions
contemplated by this Agreement, the Assumed Liabilities and any other rights or obligations to be transferred hereunder or pursuant
hereto, and Seller disclaims any other representations or warranties, whether made by Seller or any of its affiliates, officers,
directors, employees, agents or representatives.

ARTICLE
IV

REPRESENTATIONS AND WARRANTIES OF PURCHASER

Purchaser
represents and warrants to Seller as follows:

Section
4.01                    Incorporation
and Authority. Purchaser is a corporation duly incorporated, validly existing and in good standing under the laws of the State
of Delaware and has all necessary corporate power and authority to enter into this Agreement to carry out its obligations hereunder
and to consummate the transactions contemplated hereby. This Agreement has been duly and validly executed and delivered by Purchaser,
and (assuming due authorization, execution and delivery by Seller) this Agreement constitutes a legal, valid and binding obligation
of Purchaser enforceable against Purchaser in accordance with its terms.

Section
4.02                    No Conflict.
The execution, delivery and performance of this Agreement do not (a) violate or conflict with the Certificate of Incorporation
or By-laws of Purchaser, or (b) conflict with or violate any law, rule, regulation, order, writ, judgment, injunction, decree,
determination or award applicable to Purchaser except such conflicts or violations as would not prevent or delay Purchaser from
consummating the transactions contemplated by this Agreement.

Section
4.03                    No Brokers.
No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with
the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Purchaser.

Section
4.04                    Independent
Investigation. Purchaser has conducted its own independent investigation, review and analysis of the Business and the Purchased
Assets, and acknowledges that it has been provided adequate access to the personnel, properties, assets, premises, books and records,
and other documents and data of Seller for such purpose. Purchaser

    	 	15	 

    	 	 	 

    

acknowledges
and agrees that: (a) in making its decision to enter into this Agreement and to consummate the transactions contemplated hereby,
Purchaser has relied solely upon its own investigation and the express representations and warranties of Seller set forth in ARTICLE
III of this Agreement (including related portions of the Seller’s Disclosure Schedule) and (b) neither Seller nor any other
Person has made any representation or warranty as to Seller, the Business, the Purchased Assets or this Agreement, except as expressly
set forth in ARTICLE III of this Agreement (including the related portions of the Seller’s Disclosure Schedule).

ARTICLE
V

ADDITIONAL COVENANTS

Section
5.01                    Conduct
of Business Prior to the Closing. Seller covenants and agrees that, between the Agreement Date and the Closing Date, it will:

(a)               
not sell, transfer, assign, convey, license, move, relocate or otherwise dispose of any of the Purchased Assets or enter into
any contract to do any of the foregoing;

(b)              
use its best efforts to maintain the Purchased Assets and the relationships with third parties arising under the Assigned Contracts
in substantially the same condition as on the Agreement Date; and

(c)               
secure good and marketable title in Seller’s name in and to all of the Purchased Assets, free of all Encumbrances and to
cause the conditions to Closing set forth in Section 7.02 to be fulfilled as promptly as possible.

Section
5.02                    Books
and Records. If, in order to properly prepare documents required to be filed with governmental authorities (including taxing
authorities) or its financial statements, it is necessary that either party hereto or any successors be furnished with additional
information relating to the Purchased Assets, the Assumed Liabilities or the Business, and such information is in the possession
of the other party hereto, such party agrees to use its reasonable efforts to furnish such information to such other party, at
the cost and expense of the party being furnished such information and such information shall be subject to the confidentiality
obligations set forth under Section 5.03.

Section
5.03                    Confidentiality.

(a)               
Mutual Confidentiality. All copies of financial information, marketing and sales information, pricing, marketing plans,
business plans, financial and business projections, customer lists, methodologies, inventions, software, technology, know-how,
product designs, product specifications and drawings, and other confidential and/or proprietary information of a party to this
Agreement are hereinafter referred to as “Confidential Information”. A party who owns and discloses
its Confidential Information is referred to below as a “Disclosing Party” and a party who receives or
is given access to a Disclosing Party’s Confidential Information is referred to below as a “Receiving Party.”
Each party hereto agrees that all Confidential Information of another party that is disclosed to such party in the course of negotiating
the transactions contemplated by this Agreement or conducting due diligence in connection herewith will be held in confidence
and will not be used or disclosed by the Receiving Party except for the

    	 	16	 

    	 	 	 

    

purposes
relating to this Agreement for which such Confidential Information was disclosed, and will be promptly destroyed by the Receiving
Party or returned to the Disclosing Party, upon the Disclosing Party’s written request. No party’s employees will
be given access to Confidential Information of another party except on a “need to know” basis and such employees shall
be informed of the need to keep such Confidential Information confidential. It is agreed that Confidential Information will not
include information that: (i) was known to such Receiving Party before receipt of such information from the Disclosing Party;
(ii) is or becomes generally known to the public through no breach of this Section or any act or omission on the part of the Receiving
Party; (iii) is disclosed by a third party having the legal right to disclose such information with no obligation of confidence
to the Disclosing Party; or (iv) is independently developed by the Receiving Party without use of any of the Disclosing Party’s
Confidential Information. Effective upon the Closing the foregoing provisions of this Section will terminate with respect to any
obligation of Purchaser to refrain from using or disclosing or to return to Seller any Confidential Information of Seller that
relates to any of the Purchased Assets.

(b)              
Seller’s Confidential Information. All copies of financial information, marketing and sales information, pricing,
marketing plans, business plans, financial and business projections, customer lists, methodologies, inventions, software, know-how,
product designs, product specifications and drawings, and other confidential and/or proprietary information of the Seller related
to the Business or any of the Purchased Assets, including but not limited to the Documentation and the Intellectual Property Rights
(collectively, “Seller’s Confidential Information”) will, be held by Seller in strict confidence
and, at all times following the Closing, will not be used or disclosed by Seller to any third party except as required by applicable
law and, upon Purchaser’s request, will be promptly destroyed by the Seller or delivered to Purchaser after the one (1)
year anniversary of the Closing Date; except that the Seller may use internal copies of Business Records that it is entitled
to retain under Section 2.02 hereof solely to prepare and file tax returns and prepare Seller’s financial statements or
defend against any indemnification claims relating to Taxes under ARTICLE IX. It is agreed that Sellers’ Confidential Information
will not include information that is now, or later becomes, part of the general public knowledge or literature in the art,
other than as a result of a breach of this Agreement by Seller.

Section
5.04                    Regulatory
and Other Authorizations; Consents.

(a)               
Efforts. Each of Seller and Purchaser will use its respective reasonable best efforts to obtain all authorizations, consents,
orders and approvals of all federal, state and local regulatory bodies, courts and officials that are necessary for the execution
and delivery of, and the performance of its obligations pursuant to, this Agreement or any other agreements required to be entered
into by such party pursuant to this Agreement and will cooperate fully with the other party in promptly seeking to obtain all
such authorizations, consents, orders and approvals. The parties hereto will not take any action that will have the effect of
delaying, impairing or impeding the receipt of any required approvals.

(b)              
Communication. Seller, on the one hand, and Purchaser, on the other hand, will promptly inform the other of any material
communication between such party and any federal, state, local or foreign government or governmental authority or court regarding
any of the transactions contemplated by this Agreement and the Ancillary Agreements. If either Seller, Purchaser or any affiliate
thereof receives a request for additional information or for documents

    	 	17	 

    	 	 	 

    

or
any material from any such government or governmental authority with respect to the transactions contemplated hereby, then such
party will endeavor in good faith to make or cause to be made, as soon as reasonably practicable and after consultation with the
other party, an appropriate response in compliance with such request. Further, no written materials will be submitted by either
Seller or Purchaser to any federal, state, or local governmental agency, nor will any oral communications be initiated with such
governmental entities by a party, without prior disclosure to and coordination with the other party and its counsel.

Section
5.05                    Further
Actions. From and after the Closing, each of the parties hereto will execute and deliver such documents and other papers and
take such further actions as may be reasonably required to carry out the provisions of this Agreement or any other agreements
required to be entered into by such party pursuant to this Agreement and give effect to the transactions contemplated by this
Agreement and such other agreements.

Section
5.06                    Furnishing
of Outstanding Business Proposals. Prior to or concurrently with the Closing, Seller will furnish to Purchaser with copies
of all business proposals (including names and status of discussions with prospective customers and strategic partners) that are
pending or outstanding with respect to the Business.

ARTICLE
VI

TAX MATTERS

Section
6.01                    Transaction
Taxes. Seller shall be responsible for, and shall pay all excise, value added, registration, stamp, property, documentary,
transfer, sales, use and similar Taxes, levies, charges and fees incurred, or that may be payable to any taxing authority, in
connection with the transactions (including without limitation the sale, transfer, and delivery of the Purchased Assets) contemplated
by this Agreement (collectively, “Transaction Taxes”). Seller shall be responsible for preparing and
filing any tax return relating to such Transaction Taxes and shall provide a copy of such return to Purchaser. Purchaser and Seller
agree to cooperate in minimizing the amount of any such Transaction Taxes and in the filing of all necessary documentation and
all Tax returns, reports and forms with respect to all such Transaction Taxes, including any available pre-Closing filing procedures.

Section
6.02                    Straddle
Periods. All property taxes, personal property taxes and similar ad valorem obligations in respect of the Purchased
Assets that relate to periods beginning prior to the Closing Date and ending after the Closing Date (“Straddle Periods”)
shall be prorated in accordance with the rules provided in Section 164(d) of the Internal Revenue Code. Seller shall prepare and
file, or shall cause to be prepared and filed, on a timely basis, all Straddle Period tax returns. Seller shall provide each Straddle
Period tax return to Purchaser for review not less than ten (10) business days in advance of the due date thereof, and Purchaser
shall pay to Seller its prorated portion of the tax shown to be due on each such return not less than five (5) business days before
the due date of such payment.

Section
6.03                    Other
Taxes. Except as provided in Section 6.01 and Section 6.02 above, (i) Seller shall be responsible for and shall pay any and
all Taxes with respect to the

    	 	18	 

    	 	 	 

    

Purchased
Assets relating to all periods (or portions thereof) ending on or prior to the Closing Date, and (ii) Purchaser shall be responsible
for and shall pay any and all Taxes with respect to the Purchased Assets relating to all periods (or portions thereof) ending
after the Closing Date.

ARTICLE
VII

CONDITIONS TO THE CLOSING

Section
7.01                    Conditions
to Obligations of Seller. The obligations of Seller to consummate the transactions contemplated by this Agreement will be
subject to the fulfillment (or waiver by Seller in writing), at or prior to the Closing, of each of the following conditions:

(a)               
Accuracy of Representations and Warranties: The representations and warranties of Purchaser contained in ARTICLE IV of
this Agreement will be true and correct in all material respects as of the Closing, with the same force and effect as if made
as of the Closing, (other than such representations and warranties as are expressly made as of another date) and Seller will have
received a certificate to such effect, dated as of the Closing Date, executed by a duly authorized representative of Purchaser;

(b)              
Compliance with Covenants. All the covenants contained in this Agreement to be complied with by Purchaser on or before
the Closing will have been complied with and Seller will have received a certificate to such effect, dated as of the Closing Date,
executed by a duly authorized representative of Purchaser;

(c)               
No Adverse Order. No federal or state governmental authority or other agency or commission or federal or state court of
competent jurisdiction will have enacted, issued, promulgated, enforced or entered any statute, rule, regulation, injunction or
other order (whether temporary, preliminary or permanent) which is in effect and has the effect of making the transactions contemplated
by this Agreement illegal or otherwise restraining or prohibiting consummation of such transactions; provided, however,
that the parties hereto will use their reasonable best efforts to have any such order or injunction vacated on or before the
Termination Date (as defined in ARTICLE X hereof);

(d)              
No Litigation. No suit, claim, cause of action, arbitration, investigation or other proceeding contesting, challenging
or seeking to alter or enjoin or adversely affect the sale and purchase of the Purchased Assets or any other transaction contemplated
hereby will be pending or threatened;

(e)               
Assumption Agreement. Seller shall have received a counterpart of the Assumption Agreement, executed on behalf of Purchaser
by a duly authorized representative of Purchaser; and

(f)               
Other Deliveries. Purchaser will have made the other deliveries required of it by Section 2.09 hereof.

Section
7.02                    Conditions
to Obligations of Purchaser . The obligations of Purchaser to consummate the transactions contemplated by this Agreement will
be subject to the fulfillment

    	 	19	 

    	 	 	 

    

to
the satisfaction of Purchaser (or waiver by Purchaser in writing), at or prior to the Closing, of each of the following conditions:

(a)               
No Material Adverse Change. From the date of this Agreement to the Closing Date, there will have been no material adverse
change in the Purchased Assets or the Business of Seller and Purchaser will have received a certificate to such effect, dated
as of the Closing Date, executed by a duly authorized officer of Seller, it being understood that “material adverse change”
will not include any change, directly or indirectly, arising out of or attributable to: (i) changes occurring generally in the
U.S. economy,the pharmaceutical industry and the financial or securities markets in general, (ii) acts of war (whether or not
declared), armed hostilities or terrorism, (iii) any natural or man-made disasters or acts of God, (iv) any failure by the Business
to meet internal projections or forecasts or (v) any action taken by Seller as expressly contemplated or permitted by this Agreement
or with Purchaser’s consent;

(b)              
Conduct of Business. From the date of this Agreement to the Closing Date, Seller will have conducted the Business in a
manner necessary to carrying out this Agreement, except for actions expressly permitted by this Agreement, or such further matters
as may be consented to by Purchaser in writing, and Purchaser will have received a certificate to such effect, dated as of the
Closing Date, executed by a duly authorized officer of Seller;

(c)               
Closing Date Balance Sheet. Seller shall have delivered a balance sheet of Seller prepared in a manner consistent with
prior periods and which materially represents the financial status of the Company and dated as of the Closing Date (the “Closing
Date Balance Sheet”), accompanied by a certificate from a duly authorized officer of Seller, as of the Closing Date
as to the preparation and delivery of the Closing Date Balance Sheet;

(d)              
Accuracy of Representations and Warranties. The representations and warranties of Seller contained in ARTICLE III of this
Agreement will be true and correct in all material respects as of the Closing, with the same force and effect as if made as of
the Closing (other than such representations and warranties that are expressly made as of another date), and Purchaser will have
received a certificate to such effect, dated as of the Closing Date, executed by a duly authorized officer of Seller;

(e)               
Compliance with Covenants. All the covenants contained in this Agreement to be complied with by Seller on or before the
Closing will have been complied with, and Purchaser will have received a certificate of Seller to such effect, dated as of the
Closing Date, signed by a duly authorized officer of Seller;

(f)               
Seller’s Outstanding Business Proposals. Seller will have furnished to Purchaser copies of all business proposals
outstanding for the Seller’s utilization of the Purchased Assets;

(g)              
No Order. No federal or state governmental authority or other agency or commission or federal or state court of competent
jurisdiction will have enacted, issued, promulgated, enforced or entered any statute, rule, regulation, injunction or other order
(whether temporary, preliminary or permanent) which is in effect and has the effect of making any of the transactions contemplated
by this Agreement illegal or otherwise restraining or prohibiting consummation of such transactions; provided, however,
that the parties hereto will use their best efforts to have any such order or injunction vacated on or before the Termination
Date (as defined in ARTICLE X hereof);

    	 	20	 

    	 	 	 

    

(h)              
No Litigation. No suit, claim, cause of action, arbitration, investigation or other proceeding contesting, challenging
or seeking to alter, enjoin or adversely affect the sale and purchase of the Purchased Assets or any other transaction contemplated
hereby will be pending or threatened;

(i)                
Certificate of Amendment of Articles. Seller’s Board of Directors and shareholders shall have approved an amendment
of Seller’s Articles of Incorporation to change Seller’s name to any other name that does not include the word “Migralex”
or any other trademark or tradename of Seller to be sold to Purchaser hereunder, and Seller shall have delivered to Purchaser
a Certificate of Amendment signed on behalf of Seller in form sufficient for Purchaser to file with the Office of the Delaware
Secretary of State to effect the change of name;

(j)                
Release of Encumbrances. Any Encumbrance with respect to any Purchased Asset shall have been released to the satisfaction
of Purchaser;

(k)              
Third Party Consents. Seller will have obtained and delivered to Purchaser the consents, waivers and approvals from third
parties and governmental entities necessary to effect the assignment and transfer to Purchaser of the Purchased Assets free and
clear of all Encumbrances as set forth on Schedule 7.02(k) of Seller’s Disclosure Schedule;

(l)                
Shareholder Consent. The required percentage of each class of Seller’s shareholders shall have consented to this
Agreement and the transactions contemplated hereby, including an acknowledgement that the Purchase Price represents the fair market
value of the Purchased Assets;

(m)            
No Other Action. No order has been made, no petition presented, or resolution passed for the winding-up of Seller, or the
appointment of any trustee for the benefit of creditors or the preparation or commencement of any bankruptcy or insolvency proceeding;
and

(n)              
Other Deliveries. Seller will have made the other deliveries required by Section 2.08 hereof.

ARTICLE
VIII

post-closing covenants

Section
8.01                    Maintenance
of Existence. For the period of up to twelve (12) months from the Closing Date, Seller shall continue to exist as a Delaware
corporation in good standing. Seller shall not voluntarily liquidate, dissolve or wind-up its corporate affairs, nor enter into
any agreement to take such action. In the event that action is taken to require the Seller involuntarily to liquidate, dissolve
or wind-up its corporate affairs, Seller shall immediately notify Purchaser in writing and shall use all commercially reasonable
efforts to resist such involuntary action.

Section
8.02                    No Transfer.
Seller agrees that it shall not sell, pledge, hypothecate, assign or otherwise transfer, directly or indirectly, legally or beneficially,
this Agreement or any benefit hereunder.

Section
8.03                    

    	 	21	 

    	 	 	 

    

Distributions.
For the period of twelve (12) months from the Closing Date, Seller shall not pay any dividends or other distributions to any shareholder.

Section
8.04                    Bulk
Sales. Seller shall pay or otherwise satisfy in the ordinary course of business all of its liabilities and obligations. Purchaser
and Seller hereby waive compliance with the bulk transfer provisions in connection with the transactions contemplated by this
Agreement.

Section
8.05                    Customer
and Other Business Relationships. After Closing, Seller will satisfy the Excluded Liabilities in a manner which is not detrimental
to any of Purchaser’s customer relationships pursuant to the Assigned Contracts. The Seller will refer to the Purchaser
all inquiries relating to the Purchased Assets. Neither the Seller nor any of its officers, employees, agents, or shareholders,
shall take any action which would tend to diminish the value of the Transferred Assets after Closing or that would interfere with
the business of the Purchaser to be engaged in after the Closing Date, including, without limitation, disparaging the name or
business of the Purchaser. Purchaser agrees that it shall not, and it shall cause its affiliates not to, at any time, make, directly
or indirectly, any oral or written public statements or take any actions that are disparaging of, or are intended to disparage,
discredit or injure, Dr. Mauskop, his reputation or any of the products and services he offers or has offered or any of his partners,
agents, or employees. 

Section
8.06                    Product
Liability Insurance Transfer. At Closing, Seller shall transfer the product liability insurance of the Business and Purchaser
shall maintain in effect such insurance coverage for the statute of limitations period with respect to any claims arising from
the sales of the Migralex product occurring prior to the Closing Date.

Section
8.07                    Seller’s
Right to Repurchase. In the event that Purchaser ceases its efforts to commercialize the Migralex product within the first
four (4) years after the Closing Date and, within a one (1) year period thereafter, is unable to sell the Migralex product and
its related assets to a bona fide third party buyer, Seller shall have the right (but not the obligation) by delivery of written
notice to Purchaser to repurchase the Purchased Assets from Purchaser for one dollar ($1.00) on an “AS IS, WHERE IS”
basis and shall assume only the Liabilities attributable to such Purchased Assets for the period from and after Seller’s
repurchase of the Purchased Assets.

ARTICLE
IX

INDEMNIFICATION

Section
9.01                    Loss
Defined; Indemnitees. For purposes of this ARTICLE IX, the term “Loss” will mean and include any
and all liability, loss, damage, claim, expense, cost, fine, fee, penalty, obligation or injury including, without limitation,
those resulting from any and all claims, actions, suits, demands, assessments, investigations, judgments, awards, arbitrations
or other proceedings, together with reasonable costs and expenses including the reasonable attorneys’ fees and other legal
costs and expenses relating thereto. As used in this ARTICLE IX, the term “Purchaser Indemnitees” means
and includes Purchaser and any present or future

    	 	22	 

    	 	 	 

    

officer,
director, employee, affiliate, stockholder or agent of Purchaser; and the term “Seller Indemnitee” means
and includes any present or future officer, director, employee, affiliate, stockholder or agent of Seller.

Section
9.02                    Indemnification
by Seller. Seller agrees, subject to the other terms, conditions and limitations of this Agreement (including the provisions
of Section 9.05 hereof), to indemnify Purchaser and any Purchaser Indemnitee against, and to hold Purchaser and each Purchaser
Indemnitee harmless from, all Loss arising out of:

(a)               
the failure of any representation or warranty of Seller contained in ARTICLE III of this Agreement or any certificate delivered
pursuant to this Agreement, to be true and correct as of the Closing Date or the breach or violation of any covenant of Seller
made herein; and

(b)              
any of the Excluded Assets or any of the Excluded Liabilities.

Section
9.03                    Indemnification
by Purchaser. Purchaser agrees, subject to the other terms, conditions and limitations of this Agreement (including the provisions
of Section 9.04 hereof), to indemnify Seller and any Seller Indemnitee against, and to hold Seller and each Seller Indemnitee
harmless from, all Loss arising out of:

(a)               
the failure of any representation or warranty of Purchaser contained in ARTICLE IV of this Agreement or any certificate delivered
pursuant to this Agreement, to be true and correct as of the Closing Date or the breach or violation of any covenant of Purchaser
made herein; and

(b)              
any of the Assumed Liabilities.

Section
9.04                    Procedures
for Indemnification. As used herein, an “Indemnified Party” means a party seeking indemnification
pursuant to Section 9.02 or Section 9.03, and the term “Indemnifying Party” means the party who is obligated
to provide indemnification under Section 9.02 or Section 9.03. The Indemnified Party agrees to give the Indemnifying Party prompt
written notice of any event, or any claim, action, suit, demand, assessment, investigation, arbitration or other proceeding by
or in respect of a third party (a “Third-Party Claim”) of which it has knowledge, for which such Indemnifying
Party is entitled to indemnification under this ARTICLE IX; provided, that failure to so notify the Indemnifying Party of any
such claim shall discharge the Indemnifying Party of its liabilities and obligations hereunder only if and to the extent that
the Indemnifying Party is prejudiced thereby. In the case of a Third-Party Claim, the Indemnifying Party will have the right to
direct, through counsel of its own choosing, the defense or settlement of any such Third-Party Claim at its own expense. In such
case the Indemnified Party may participate in such defense, but in such case the expenses of the Indemnified Party will be paid
by the Indemnified Party. The Indemnified Party will promptly provide the Indemnifying Party with access to the Indemnified Party’s
records and personnel relating to any such Third-Party Claim during normal business hours and will otherwise cooperate with the
Indemnifying Party in the defense or settlement of such Third-Party Claim, and the Indemnifying Party will reimburse the Indemnified
Party for all its reasonable out-of-pocket costs and expenses incurred in providing such access, personnel and cooperation. Upon
assumption of the defense of any such Third-Party Claim by the Indemnifying Party, the

    	 	23	 

    	 	 	 

    

Indemnified
Party will not pay, or permit to be paid, any part of any claim or demand arising from such Third-Party Claim, unless the Indemnifying
Party consents in writing to such payment (which consent will not be unreasonably withheld) or unless a final judgment from which
no appeal may be taken by or on behalf of the Indemnified Party is entered against the Indemnified Party for such liability. No
such Third-Party Claim may be settled by the Indemnifying Party without the written consent of the Indemnified Party, which consent
will not be unreasonably withheld. If the Indemnifying Party fails to defend or fails to prosecute or withdraws from such defense,
then the Indemnified Party will have the right to undertake the defense or settlement thereof, at the Indemnifying Party’s
expense. If the Indemnified Party assumes the defense of any such Third-Party Claim pursuant to this Section 9.04 and proposes
to settle such Third-Party Claim prior to a final judgment thereon or to forgo appeal with respect thereto, then the Indemnified
Party will give the Indemnifying Party prompt written notice thereof and the Indemnifying Party will have the right to participate
in the settlement or assume or reassume the defense of such Third-Party Claim.

Section
9.05                    Limitations
on Indemnification. Notwithstanding anything herein to the contrary, no claim for indemnification under this ARTICLE IX may
be brought after the twelve (12) month period following the Closing Date; provided, however, that claims for indemnification
relating to Taxes (including without limitation Transaction Taxes) may be brought at any time prior to the expiration of the applicable
statute of limitation. The provisions for indemnity under ARTICLE IX shall be effective only when (a) the Losses for which indemnification
is sought exceeds on a cumulative basis an amount equal to $50,000, and then only to the extent of any such excess. In the event
of any claim for indemnification under ARTICLE IX, the aggregate liability of either party shall in no event exceed $250,000.
Except for any claims arising out of or relating to the intentional fraud of any party, from and after the Closing, the indemnification
provided pursuant to this ARTICLE IX, shall be the sole and exclusive remedy hereto for any Losses as a result of, with respect
to or arising out of the breach of this Agreement. In no event shall any Person be liable to another Person for (and the term
Losses shall exclude) any indirect, special, consequential, lost profits, multiple of any financial measure, exemplary, diminution
in value or punitive damages with respect to the transactions contemplated hereby. 

Section
9.06                    Sole
Remedy/Waiver. Should the Closing occur, the remedies provided for in this ARTICLE IX shall be the sole and exclusive remedies
of any Indemnified Party in respect of Losses arising out of this Agreement, the Ancillary Agreements, the Purchased Assets, the
Excluded Assets, the Assumed Liabilities, the Excluded Liabilities or the transactions contemplated hereby or by the Ancillary
Agreements, other than (i) for actions for specific performance or other equitable remedies or (ii) for claims against a party
arising out of the intentional fraud of such party. In furtherance of the foregoing, each party hereby waives (on behalf of itself
and the relevant Indemnified Parties) any provision of applicable law to the extent that it would limit or restrict the agreement
contained in this Section 9.06, and each party hereby waives (on behalf of itself and the relevant Indemnified Parties)
for periods following the Closing any and all other rights, claims or causes of action it or its affiliates or relevant Indemnified
Parties may have against the other party or its affiliates or representatives now or in the future arising under or based upon
this Agreement, any Ancillary Agreement, any document or certificate delivered in connection herewith, other than the remedies
provided in this ARTICLE IX or contained in any Ancillary Agreement.

ARTICLE
X

    	 	24	 

    	 	 	 

    

TERMINATION, AMENDMENT AND WAIVER

Section
10.01                Termination. This Agreement
may be terminated at any time prior to the Closing:

(a)               
by the mutual written consent of Seller and Purchaser; or

(b)              
by Purchaser, if the Closing will not have occurred prior to March 31, 2016 (the “Termination Date”);
provided, however, that the right to terminate this Agreement under this Section 10.01(b) will not be available to any
party whose failure to fulfill any obligation under this Agreement will have been the primary cause of, or will have resulted
in, the failure of the Closing to occur prior to such date; or

(c)               
by either Seller or Purchaser if there will have been instituted, pending or threatened (and not withdrawn) any action or proceeding
by any governmental authority or administrative agency before any governmental authority, administrative agency or court of competent
jurisdiction, or there will be in effect any judgment, decree or order of any governmental authority, administrative agency or
court of competent jurisdiction, in either case, seeking to prohibit or limit Purchaser from exercising all material rights and
privileges pertaining to its ownership of the Purchased Assets or the ownership or operation by Purchaser or any of its subsidiaries
of all or a material portion of the Purchased Assets, or seeking to compel Purchaser or any of its subsidiaries to dispose of
or hold separate all or any material portion of the Purchased Assets.

Section
10.02                Effect of Termination.
In the event of termination of this Agreement in accordance with Section 10.01 hereof, this Agreement will forthwith become void
and there will be no liability on the part of any party hereto except as set forth in Section 11.01, provided, however,
that nothing herein will relieve either party from liability for any willful breach hereof; provided, further, however,
that the provisions of Section 5.03(a) shall survive any termination of this Agreement.

Section
10.03                Waiver. At any time prior
to the Closing, any party hereto may (i) extend the time for the performance of any of the obligations or other acts of the other
parties hereto, (ii) waive any inaccuracies in the representations and warranties contained herein or in any document delivered
pursuant hereto or (iii) waive compliance with any of the agreements or conditions contained herein. Any such extension or waiver
will be valid if set forth in an instrument in writing signed by the party to be bound thereby.

ARTICLE
XI

DISPUTE RESOLUTION

Section
11.01                Submission Of Claims To Arbitration.
Any and all controversies or claims arising out of or relating to this Agreement, or the breach thereof shall be settled by to
binding arbitration held in Washington, D.C. administered by the Judicial Arbitration and

    	 	25	 

    	 	 	 

    

Mediation
Service (“JAMS”) and shall be conducted (except to the extent otherwise specifically provided
for in this Agreement) under the JAMS’ then-effective commercial arbitration rules, and judgment on the award rendered by
the arbitrator may be entered in any court having jurisdiction thereof; provided, however, that a controversy or claim otherwise
subject to arbitration hereunder may initially be heard by any court of competent jurisdiction to the extent, and only to the
extent, that initial submission of the matter to a court is necessary for a party to seek emergency injunctive relief, and provided,
further, however, that the matter initially submitted to a court shall be remanded by the court to arbitration pursuant to this
Section 11.01 as soon as the matter as to which such emergency injunctive relief was sought has been heard by the court.

Section
11.02                Fees and Costs. The prevailing
party in any arbitration brought under ARTICLE XI shall be entitled to recover, as an element of the costs of the arbitration
and not as damages, its reasonable attorneys’ fees, experts’ fees and other costs and expenses incurred in such arbitration
to be fixed by the arbitrator (including without limitation, costs, expenses and fees on any appeal and costs, expenses and fees
in any initial proceedings before any court).

ARTICLE
XII

GENERAL PROVISIONS

Section
12.01                Expenses. All costs, expenses
or fees, including, without limitation, fees and disbursements of counsel, financial advisors, accountants, brokers, finders or
investment bankers, incurred in connection with this Agreement and the transactions contemplated hereby will be paid by the party
incurring such costs and expenses, whether or not the Closing will have occurred.

Section
12.02                Notices. All notices, requests,
claims, demands and other communications hereunder will be in writing and will be given or made (and will be deemed to have been
duly given or made upon receipt) by delivery in person, by courier service, by cable, by telecopy, by telegram, by telex or by
registered or certified mail (postage prepaid, return receipt requested) to the parties at the following addresses (or at such
other address for a party as will be specified by like notice):

(a)               
if to Seller:

Migralex,
Inc.

30
East 76th Street

New
York, NY 10021

Attention:
Alexander Mauskop

Email:
drmauskop@nyheadache.com

 

with
a copy (which shall not constitute notice) to:

 

    	 	26	 

    	 	 	 

    

Morgan,
Lewis & Bockius LLP

502 Carnegie Center

Princeton, NJ 08540

Facsimile: (609) 919-6701

Attention: Randall Sunberg

Emilio Ragosa

Email:
rsunberg@morganlewis.com

emilio.ragosa@morganlewis.com

 

(b)              
if to Purchaser:

Joseph
Hernandez

135
East 57th Street, 24th Floor

New
York, NY 10022

Section
12.03                Public Announcements. Except
as may otherwise be required by law, Seller will not make any public announcements in respect of this Agreement or the transactions
contemplated herein or otherwise communicate with any news media without prior notification to Purchaser, and, to the maximum
extent practicable, the parties will cooperate as to the timing and contents of any such announcement.

Section
12.04                Headings. The headings
contained in this Agreement are for reference purposes only and will not affect in any way the meaning or interpretation of this
Agreement.

Section
12.05                Severability. If any term
or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of law or public policy, all
other conditions and provisions of this Agreement will nevertheless remain in full force and effect so long as the economic or
legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party. Upon such
determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto will negotiate
in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually
acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the greatest
extent possible.

Section
12.06                No Joint Venture.
Nothing contained in this Agreement shall be deemed or construed as creating a joint venture or partnership between the parties
hereto. No party is by virtue of this Agreement authorized as an agent, employee or legal representative of any other party. No
party shall have the power to control the activities and operations of any other and their status is, and at all times shall continue
to be, that of independent contractors with respect to each other. No party shall have any power or authority to bind or commit
any other party. No party shall hold itself out as having any authority or relationship in contravention of this Section 12.06.

Section
12.07                Entire Agreement. This
Agreement and the Ancillary Agreements constitute the entire agreement of the parties hereto with respect to the subject matter
hereof and

    	 	27	 

    	 	 	 

    

supersede
all prior agreements and undertakings with respect to the subject matter hereof, both written and oral.

Section
12.08                Assignment. This Agreement
will not be assigned by Purchaser or Seller without the prior written consent of the non-assigning party; provided, however,
that Purchaser may assign all or a portion of its rights and obligations hereunder to one or more wholly-owned subsidiaries of
Purchaser; and provided further, that any party may assign its rights and obligations hereunder to a person that acquires
control of such party by merger, consolidation or a sale of all or substantially all of such party’s assets or by acquisition
of voting stock of such party representing more than fifty percent (50%) of the total voting power of all outstanding securities
of such party, provided such person agrees in writing to be bound by all of its assignor’s obligations under this Agreement.

Section
12.09                No Third-Party Beneficiaries.
This Agreement is for the sole benefit of the parties hereto and their permitted assigns and nothing herein, express or implied,
is intended to or will confer upon any other person or entity any legal or equitable right, benefit or remedy of any nature whatsoever
under or by reason of this Agreement, except for the indemnification rights of Purchaser Indemnitees and Seller Indemnitees under
ARTICLE IX hereof.

Section
12.10                Amendment; Waiver. This
Agreement may not be amended or modified except by an instrument in writing signed by Seller and Purchaser. Waiver of any term
or condition of this Agreement will only be effective if in writing and will not be construed as a waiver of any subsequent breach
or waiver of the same term or condition, or a waiver of any other term or condition of this Agreement.

Section
12.11                Joint Work Product. This
Agreement is a joint work product of the parties, and there is no presumption as to any party’s role in the drafting of
this Agreement.

Section
12.12                Governing Law; Venue. This
Agreement will be governed by, and construed in accordance with, the internal laws of the State of New York applicable to contracts
executed and performed entirely therein, without regard to the principles of choice of law or conflicts or law of any jurisdiction.

Section
12.13                Counterparts. This Agreement
may be executed in one or more counterparts, and by the different parties hereto in separate counterparts, each of which when
executed will be deemed to be an original but all of which taken together will constitute one and the same agreement.

Section
12.14                Restriction on Disclosure of
Agreement Terms. Neither Purchaser, on the one hand, nor Seller, on the other hand, shall publicly disclose or announce the
price being paid by Purchaser for the Purchased Assets hereunder or the detailed terms and conditions of this Agreement (other
than to such party’s employees, directors or advisors), without the other party’s prior consent; provided,
however, that notwithstanding the foregoing, a party may make such disclosures regarding this Agreement as it determines
with the advice of its legal counsel, are required under applicable laws and regulations or orders, decrees, inquiries or subpoenas
of

    	 	28	 

    	 	 	 

    

any
court or governmental body, and in that case such party will give the other party or parties hereto prior notice of its intention
to make such disclosure pursuant to this proviso.

Section
12.15                Specific Performance. The
parties hereto acknowledge that money damages would not be an adequate remedy at law if any party fails to perform in any material
respect any of its obligations hereunder and accordingly agree that each party, in addition to any other remedy to which it may
be entitled at law, in equity or, after the Closing, as provided in this Agreement, shall be entitled to seek to compel specific
performance of the obligations of any other party under this Agreement and appropriate injunctive relief may be applied for and
granted in connection therewith, in each case, without the posting of any bond, in accordance with the terms and conditions of
this Agreement in any court of the United States or any state thereof having jurisdiction, and if any action should be brought
in equity to enforce any of the provisions of this Agreement, none of the parties hereto shall raise the defense that there is
an adequate remedy at law. No remedy permitted under this Agreement shall be exclusive of any other remedy permitted under this
Agreement.

[The
remainder of this page has been intentionally left blank]

    	 	29	 

    	 	 	 

    

IN
WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the date first written above by their respective
officers thereunto duly authorized.

MIGRALEX,
INC.

By:
/s/ Alexander Mauskop 

Name: Alexander Mauskop
 Title: President

EMBER
THERAPEUTICS, INC.

By:
/s/ Joseph Hernandez
 Name:
Joseph Hernandez
 Title: Executive Chairman 

    	 	30	 

    	 	 	 

    

EXHIBIT
A

Assigned
Contracts

All
of the contracts (i) listed on the .PDF titled “Exhibit A – Business Contracts – Migralex Key Csr list.pdf”
and (ii) uploaded to the following URLs https://www.dropbox.com/sh/cs98jdo6ail479w/AAB_wvS06kpT360b8oJx5nFva?dl=0 and https://www.dropbox.com/sh/qwf68ghnr909xtz/AACm2sLLWMd1PH4KUasZUwRJa/Migralex%20Legal%20Agreements?dl=0.

    	 	31	 

    	 	 	 

    

SELLER’S
DISCLOSURE SCHEDULE

provided
pursuant to the

ASSET
PURCHASE AGREEMENT,

(the
“Agreement”)

dated
as of March 18, 2016,

by
and between

MIGRALEX,
INC.

and

EMBER
THERAPEUTICS, INC.

 

The
Seller’s Disclosure Schedule is being delivered by Seller pursuant to, and is made a part of, the Agreement. Unless otherwise
specifically indicated, all capitalized terms used in the Seller’s Disclosure Schedule shall have the respective meanings
assigned to them in the Agreement.

 

The
information contained in the Seller’s Disclosure Schedule is disclosed solely for the purposes of qualifying and limiting
the representations and warranties of Seller contained in and shall not be deemed to expand in any way the scope or effect of
any such representations or warranties. No disclosure contained herein shall be deemed to be an admission to any third party of
any matter whatsoever, including of any violation of law or breach of any agreement.

The
Seller’s Disclosure Schedule may include items or information which Seller is not required to disclose under the Agreement,
and disclosure of such items or information shall not affect (directly or indirectly) the interpretation of the Agreement or the
scope of the disclosure obligations thereunder. Such additional items are set forth for informational purposes only, and the Seller’s
Disclosure Schedule do not necessarily include other items of a similar nature. Inclusion of any item in the Seller’s Disclosure
Schedule do not constitute an admission by Seller that such item is material in any respect or did not arise in the ordinary course
of business or that such item is reasonably likely to result in a material adverse change.

 

The
Seller’s Disclosure Schedule have been arranged in sections and subsections corresponding to the sections and subsections
of the Agreement; provided, however, the disclosure of any item in any section or subsection of the Seller’s
Disclosure Schedule shall be deemed disclosure with respect to any other section or subsection of the Seller’s Disclosure
Schedule to the extent it is reasonably apparent on its face that such information is applicable to such other section of the
Seller’s Disclosure Schedule .

 

The
headings contained in the Seller’s Disclosure Schedule are solely for convenience of reference and shall not affect the
meaning or interpretation of the Seller’s Disclosure Schedule, the Agreement or of any item, term or provision hereof or
thereof.

    	 	32	 

    	 	 	 

    

Schedule
3.03 

(Consents
and Approvals)

 

1.     
Vendor Agreement, dated October 2013, between Seller and drugstore.com, inc.

 

2.     
Licensing Agreement, [date unknown], between Seller and GS1 US.

 

3.     
Client Services Agreement, dated December 21, 2012, between Seller and Media Design Group, LLC.

 

4.     
Mutual Confidentiality Agreement, dated August 7, 2014, between Seller and Tedor Pharma Inc.

 

5.     
Insertion Order, dated March 18, 2013, between Seller and ValusDirect, LLC.

 

6.     
Service Agreement, dated March 28, 2013, between Seller and West Direct, LLC.

 

    	 	33	 

    	 	 	 

    

Schedule
3.05

(Accounts
Receivable)

 

See
attached.

 

    	 	34	 

    	 	 	 

    

Schedule
3.08

(Taxes)

 

None.

 

    	 	35	 

    	 	 	 

    

Section
3.10

(Compliance
with Laws)

 

In
May 2013, Seller’s counsel, Manatt, Phelps & Phillips, LLP, responded to a letter from the National Advertising Review
Council (“NARC”), dated March 22, 2013, in which the NARC identified several claims that had been made
for the Migralex product and requested substantiation. In this letter, Seller indicated that all such claims related to discontinued
claims and provided substantiation that all of the remaining advertising claims remain truthful and accurate.

 

 

    	 	36	 

    	 	 	 

    

Schedule
3.13

(Contracts)

 

Seller
is finalizing a refund to Meijer’s of $7,835 in connection with certain expired inventory.

 

    	 	37	 

    	 	 	 

    

Schedule
3.14

(Governmental
Contracts)

 

None.

    	 	38	 

    	 	 	 

    

Schedule
3.15

(Oral
Contracts)

 

None.

 

    	 	39	 

    	 	 	 

    

Schedule
3.16

(Liabilities)

 

See
attached balance sheet, P&L statement and list of accounts receivable.

 

Seller
is finalizing a refund to Meijer’s of $7,835 in connection with certain expired inventory.

 

Seller
holds a deposit of $2,268.65 for operating capital.

 

    	 	40	 

    	 	 	 

    

ASSIGNMENT
AND ASSUMPTION
AGREEMENT

 

THIS
ASSIGNMENT
AND
ASSUMPTION
AGREEMENT,
dated as of March [●], 2016 (this “Agreement”), is made by MIGRALEX, INC., a Delaware corporation
(“Assignor”), in favor of EMBER THERAPEUTICS, INC., a Delaware corporation (“Assignee”).
All capitalized
terms used herein
but not otherwise
defined shall
have the respective
meanings
ascribed
to them in the Purchase
Agreement
(as defined
below).

 

WHEREAS,
the Assignor
and the Assignee
have entered
into that certain
Asset Purchase
Agreement,
dated
as of March 18, 2016 (the
“Purchase
Agreement”),
pursuant
to which the Assignor
has agreed
to sell, assign,
transfer,
convey
and deliver
to the Assignee,
and the Assignee
has agreed
to purchase,
acquire
and accept
from the Assignor,
the entire
right,
title and interest of
the Assignor,
to the extent
assignable,
in, to and under
the Purchased
Assets; and

 

WHEREAS,
pursuant to the
Purchase
Agreement,
the Assignee
has agreed
to assume, pay,
discharge
or perform
when due,
as appropriate,
the Assumed
Liabilities.

 

NOW,
THEREFORE,
in consideration of
the representations,
warranties,
covenants
and agreements
set forth
in the Purchase
Agreement
and other
good and valuable
consideration,
the receipt and sufficiency
of which
are hereby
acknowledged,
and intending
to be legally
bound, the Assignor
and the Assignee
hereby
agree
as follows:

 

1.                         
Assumption. The Assignor
hereby
assigns,
and the
Assignee
hereby
assumes and
agrees to pay,
discharge
and perform
when due,
as appropriate,
the Assumed
Liabilities.

 

2.                         
No Conflict,
Inconsistency
or Merger.
Each of
the Assignor
and the Assignee,
by its execution
of this Agreement,
hereby
acknowledges
and agrees
that the representations,
warranties
and covenants
under the
Purchase
Agreement
shall not be deemed
to be merged,
enlarged,
diminished, modified
or altered
in any
way by
this instrument, and
in the event of
any conflict,
the terms of
the Purchase
Agreement
shall prevail.

 

3.                         
Successors and
Assigns.
 This Agreement
shall bind and
inure to the
benefit
of the Assignor
and the Assignee
and their
respective
successors
and permitted
assigns.

 

4.                         
No Third Party
Beneficiaries.
The terms and
provisions
of this Agreement
are intended
solely
for the
benefit of
the parties
hereto
and their
respective
successors
and permitted
assigns, and
it is not the intention of
the parties
to confer
third-party
beneficiary
rights,
and this Agreement
does not confer
any
such rights,
upon any
other
Person.

 

5.                         
Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which
together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other
means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this
Agreement.

 

6.                         
Successors and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their
respective successors and assigns.

    	 	41	 

    	 	 	 

    

 

7.                         
Governing Law. The provisions hereof shall be governed and interpreted in all respects pursuant to the substantive laws
of the State of New York without regard to its conflict of laws principles.

 

[Signature
Page
Follows.]

 

 

    	 	42	 

    	 	 	 

    

 

IN
WITNESS WHEREOF, the
parties have duly
executed this Agreement
as of the
date first written above.

 

 

 

ASSIGNOR:

 

MIGRALEX,
INC.

 By: /s/ Alexander Mauskop 

Name: Alexander Mauskop

Title: President 

 

 

ASSIGNEE:

 

EMBER
THERAPEUTICS, INC.

By:
/s/ Joseph Hernandez
 Name:
Joseph Hernandez
 Title: Executive Chairman 

    	 	43	 

    	 	 	 

    

EXHIBIT
B

 

BILL
OF SALE

BILL
OF SALE, made, executed and delivered on March ___, 2016, Migralex, Inc., a Delaware corporation (the “Seller”), acting
on behalf of itself and all of its subsidiary and affiliated companies, and Ember Therapeutics, Inc., a Delaware corporation (the “Purchaser”).

WITNESSETH

WHEREAS,
the Seller and the Purchaser are parties to that certain Asset Purchase Agreement dated March 18, 2016 by and between Purchaser
and Seller (the “Agreement”), providing for, among other things, the transfer and sale to the Purchaser
of the Purchased Assets, and on the terms and conditions provided in the Agreement.

WHEREAS,
the Purchaser and the Seller now desire to carry out the intent and purpose of the Agreement by the Seller’s execution and
delivery to the Purchaser of this instrument evidencing the sale, conveyance, assignment, transfer and delivery to the Purchaser
of the Purchased Assets, subject to the Assumed Liabilities and subject to the terms and conditions of the Agreement.

NOW,
THEREFORE, in consideration of the foregoing premises and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Seller does hereby, effective from and after the date hereof, sell, convey, assign, transfer
and deliver unto the Purchaser and its successors and assigns, forever, the entire right, title and interest in, to and under
the Purchased Assets, subject only to the Assumed Liabilities and subject to the terms and conditions of the Agreement and free
and clear of Encumbrances.

TO
HAVE AND TO HOLD the Purchased Assets unto the Purchaser, its successors and assigns, FOREVER.

This
Bill of Sale shall be construed and enforced in accordance with applicable federal law and the laws (other than the conflict of
law rules) of the State of New York.

In
the event that any provision of this Bill of Sale is construed to conflict with a provision of the Agreement, the provision of
the Agreement shall be deemed to be controlling.

This
instrument shall be binding upon and shall inure to the benefit of the respective successors and assigns of the Seller and the
Purchaser.

[The
rest of this page intentionally left blank]

    	 	44	 

    	 	 	 

    

 

IN
WITNESS WHEREOF, this Bill of Sale has been duly executed and delivered by a duly authorized representative of the Seller on the
date first above written.

 

	 	 	 
	Migralex,
    Inc.
	 	 
	By		/s/ Alexander
    Mauskop
	 		Name: Alexander Mauskop
	 		Title: President

    	 	45	 

    	 	 	 

    

EXHIBIT
C

 

CONSULTING
AGREEMENT

 

           
THIS CONSULTING AGREEMENT (the "Agreement") is made and entered into this day of March __, 2016, (the
"Effective Date") by and between Ember Therapeutics, Inc., a Delaware corporation duly organized under law and
having an usual place of business at 135 East 57th Street, 24th Floor, New York, NY 10022 (hereinafter referred
to as the "Company") and Dr. Alex Mauskop (hereinafter referred to as the "Consultant") residing
at 30 East 76th Street #2A, New York, NY 10021.

 

           
WHEREAS, the Company wishes to engage the Consultant to provide the services described herein and Consultant agrees to
provide the services for the compensation and otherwise in accordance with the terms and conditions contained in this Agreement.

 

           
NOW THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, accepted and agreed to, the Company and the Consultant, intending to be legally bound, agree
to the terms set forth below.

 

1.        
TERM.  Commencing as of the Effective Date, and continuing for a period of three (3) years (the "Term"),
unless earlier terminated pursuant to Article 5 hereof, the Consultant agrees that he will serve as a consultant to the Company. 
This Agreement may be renewed or extended for any period as may be agreed by the parties.

 

		2.	DUTIES
                                         AND SERVICES.

 

           
(a)        Consultant's duties and responsibilities shall be to provide medical advice, marketing
support, trial design (when appropriate), operational and strategic advice and support to the company and its CEO in the company’s
operational execution, fund raising, marketing, development efforts, including financial and strategic planning, vendor selection
and management. In addition, the Consultant shall use reasonable commercial diligence in promoting the transaction and the commercial
efforts of the product, including, but not limited to interviews, guest appearances, commercial participation and speaker engagements
and other related material and work as requested by the Company, the Executive management personnel or Board of Directors. The
Consultant shall report directly to the Chairman (collectively, the "Duties" or "Services").

 

           
(b)        The Consultant represents and warrants to the Company that he is under no contractual
or other restrictions or obligations which are inconsistent with the execution of this Agreement, or which will interfere with
the performance of his Duties.  Consultant represents and warrants that the execution and performance of this Agreement will
not violate any policies or procedures of any other person or entity for which he performs Services concurrently with those performed
herein.

 

    	 	46	 

    	 	 	 

    

           
(c)        In performing the Services, Consultant shall comply, to the best of his knowledge,
with all business conduct, regulatory and health and safety guidelines established by the Company for any governmental authority
with respect to the Company’s business. 

 

3.        
CONSULTING FEE.

 

           
(a)        Subject to the provisions hereof, the Company shall pay Consultant a hourly consulting
fee of $250 per hour, paid monthly (the "Consulting Fee"). The Consultant shall perform a minimum of twenty (20)
hours of work per month. The Consultant acknowledges that the Consulting Fee and the Royalty Payments are the only form of compensation
provided for his services.

 

           
(b)        Consultant shall be entitled to prompt reimbursement for all pre-approved expenses
incurred in the performance of his Duties, upon submission and approval of written statements and receipts in accordance with
the then regular procedures of the Company. 

           

           
(c)        The Consultant agrees that all Services will be rendered by him as an independent
contractor and that this Agreement does not create an employer-employee relationship between the Consultant and the Company. 
The Consultant shall have no right to receive any employee benefits including, but not limited to, health and accident insurance,
life insurance, sick leave and/or vacation. The Consultant agrees to pay all taxes including, self-employment taxes due in respect
of the Consulting Fee and to indemnify the Company in the event the Company is required to pay any such taxes on behalf of the
Consultant.

 

		4.	ROYALTY
                                         PAYMENT.

 

(a)The
Company shall, during the Term, within ninety (90) days after the end of each successive one (1) year period after the date hereof
(each such period, an "Annual Period"), pay to the Consultant a fee equal to ***(***) of the Sales (as defined
below) by the Company and its affiliates of all Migralex products (the "Products") during the preceding Annual
Period (each such payment, a "Royalty Payment"), it being understood that the Company and
its affiliates shall use reasonable best efforts to achieve fair market value in respect of the sale and/or supply of the Products.
For purposes of this Agreement, "Sales" means the gross amount billed or invoiced by the Company or any of its
affiliates for the Products sold and/or supplied during an Annual Period, but shall exclude samples or other promotional offers
where no revenues are received for the Products.

 

(b)In
connection with the Royalty Payments made to the Consultant under Section 4(b), the Company shall furnish to the Consultant
within thirty (30) days following the end of each Annual Period, a report showing (i) the Sales for the Products and number of
units of the Products sold during such period and (ii) the amount of the Royalty Payment payable hereunder in respect of such
Sales during such period.

    	 	47	 

    	 	 	 

    

(c)The
Company shall, and shall obligate its affiliates to, keep full and accurate records of the Company’s or its affiliates’
sales of the Products to reasonably enable the Consultant or his representatives to (i) calculate and verify the Sales of the
Products during each Annual Period, and (ii) calculate and verify the Royalty Payments payable hereunder in respect of such Sales.
Such records shall be kept at the Company’s or its affiliates’ principal place of business and, with all necessary
supporting data, books and ledgers during the Term and for a period of three (3) years thereafter.

 

(d)The
Consultant shall have the right for a period of three (3) years after each Royalty Payment is made to the Consultant to appoint,
at its expense, an independent certified public accountant reasonably acceptable to the Company to audit the relevant records
of the Company to verify that the amounts of the Royalty Payment was correctly determined. Upon the request of the Consultant,
the Company shall, upon thirty (30) days written notice from the Consultant and during regular business hours at such place or
places where such records are customarily kept, make its records available for audit by the independent certified public accountant
selected by the Consultant to verify that such Royalty Payment was correctly determined. Such audit right shall not be exercised
by the Consultant more than once in any year and no period may be audited more than once. The Consultant shall treat as Confidential
Information all such records made available for audit. The results of each audit, if any, shall be reported in writing to the
Company promptly (but in no event later than thirty (30) days thereafter) after the audit and shall be binding on both the Consultant
and the Company. The Consultant shall bear the full cost of such audit unless such audit discloses, and is verified by a mutually
agreed to third party, an under-payment by the Company of more than twenty percent (20%) of the relevant amount of royalties in
any year, in which case the Company shall reimburse the Consultant for all costs incurred by the Consultant in connection with
such audit not to exceed fifty thousand dollars ($50,000). In the event there is an under-payment to the Consultant, the amount
of such underpayment shall be paid to the Consultant within five (5) business days of receiving a copy of the audit report. If
the discrepancy is an over-payment to the Consultant, the amount of such over-payment shall be paid to the Company within five
(5) business days of receiving a copy of the audit report.

 

		5.	EARLY
                                         TERMINATION OF THE TERM.

 

(a)       
If the Consultant voluntarily ceases performing his Duties, becomes physically or mentally unable to perform his Duties, or is
terminated for cause, then, in each instance, the Consulting Fee shall cease and terminate as of such date. Any termination for
"Cause" shall be made in good faith. Termination for "Cause" shall mean termination of this Agreement by the
Company because of (i) the Consultant’s willful, intentional or grossly negligent failure to perform his duties under this
Agreement, (ii) conduct on the part of the Consultant that demonstrated dishonesty or deceit in his dealings with the Company,
or (iii) the conviction of the Consultant or the plea of guilty or nolo contendere of any crime involving moral turpitude or any
felony.

 

           
(b)        Upon termination under Section 5(a), neither party shall have any further obligations
under this Agreement, except for the obligations which by their terms survive

    	 	48	 

    	 	 	 

    

this
termination as noted in Section 17 hereof.  Upon termination and, in any case, upon the Company’s request, the Consultant
shall return immediately to the Company all Confidential Information, as hereinafter defined, and copies thereof.

 

6.        
RESTRICTED ACTIVITIES. During the Term and for a period of five (5) year thereafter, Consultant will not, directly or indirectly:

 

           
(i)         solicit or request any employee of or consultant to the Company to leave the
employ of or cease consulting for the Company;

 

           
(ii)        solicit or request any employee of or consultant to the Company to join the employ
of, or begin consulting for, any individual or entity that researches, develops, markets or sells products that compete with those
of the Company;

 

           
(iii)       solicit or request any individual or entity that researches, develops, markets or sells
products that compete with those of the Company, to employ or retain as a consultant any employee or consultant of the Company;
or

 

           
(iv)       induce or attempt to induce any supplier or vendor of the Company to terminate or breach
any written or oral agreement or understanding with the Company.

 

7.        
PROPRIETARY RIGHTS.

 

           
(a)        Definitions.  For the purposes of this Article 7, the terms set forth
below shall have the following meanings:

 

                       
(i)         Concept and Ideas.  Those concepts and ideas disclosed by the
Company to Consultant or which are first developed by Consultant during the course of the performance of Services hereunder and
which relate to the Company's present, past or prospective business activities, services, and products, all of which shall remain
the sole and exclusive property of the Company.  The Consultant shall have no publication rights and all of the same shall
belong exclusively to the Company. 

 

                       
(ii)        Confidential Information. For the purposes of this Agreement, "Confidential
Information" shall mean and collectively include: all information relating to the business, plans and/or technology of the
Company including, but not limited to technical information including inventions, methods, plans, processes, specifications, characteristics,
assays, raw data, scientific preclinical or clinical data, records, databases, formulations, clinical protocols, equipment design,
know-how, experience, and trade secrets; developmental, marketing, sales, customer, supplier, consulting relationship information,
operating, performance, and cost information; computer programming techniques whether in tangible or intangible form, and all
record bearing media containing or disclosing

    	 	49	 

    	 	 	 

    

the
foregoing information and techniques including, written business plans, patents and patent applications, grant applications, notes,
and memoranda, whether in writing or presented, stored or maintained in or by electronic, magnetic, or other means.

 

                       
Notwithstanding the foregoing, the term "Confidential Information" shall not include any information which: (a) can
be demonstrated to have been in the public domain or was publicly known or available prior to the date of the disclosure to Consultant;
(b) can be demonstrated in writing to have been rightfully in the possession of Consultant prior to the disclosure of such information
to Consultant by the Company; (c) becomes part of the public domain or publicly known or available by publication or otherwise,
not due to any unauthorized act or omission on the part of Consultant; or (d) to the knowledge of the Consultant, is supplied
to Consultant by a third party without binder of secrecy, so long as that such third party has no obligation to the Company or
any of its affiliated companies to maintain such information in confidence.

 

           
(b)        Non-Disclosure to Third Parties.  Except as required by Consultant's
Duties, Consultant shall not, at any time now or in the future, directly or indirectly, use, publish, disseminate or otherwise
disclose any Confidential Information, Concepts, or Ideas to any third party without the prior written consent of the Company
which consent may be denied in each instance and all of the same, together with publication rights, shall belong exclusively to
the Company.

 

           
(c)        Documents, etc.  All documents, diskettes, tapes, procedural manuals,
guides, specifications, plans, drawings, designs and similar materials, lists of present, past or prospective customers, customer
proposals, invitations to submit proposals, price lists and data relating to the pricing of the Company's products and services,
records, notebooks and all other materials containing Confidential Information or information about Concepts or Ideas (including
all copies and reproductions thereof), that come into Consultant's possession or control by reason of Consultant's performance
of the relationship, whether prepared by Consultant or others: (a) are the property of the Company, (b) will not be used by Consultant
in any way other than in connection with the performance of his Duties, (c) will not be provided or shown to any third party by
Consultant, (d) will not be removed from the Company's or Consultant’s premises (except as Consultant's Duties require),
and (e) at the termination (for whatever reason), of Consultant's relationship with the Company, will be left with, or forthwith
returned by Consultant to the Company.

 

(d)              
Patents, etc.  The Consultant agrees that the Company is and shall remain the exclusive owner of the Confidential
Information and Concepts and Ideas.  Any interest in patents, patent applications, inventions, technological innovations,
trade names, trademarks, service marks, copyrights, copyrightable works, developments, discoveries, designs, processes, formulas,
know-how, data and analysis, whether registrable or not ("Developments"), which Consultant, as a result of rendering
Services to the Company under this Agreement, may conceive or develop, shall: (i) forthwith be brought to the attention of the
Company by Consultant and (ii) belong exclusively to the

    	 	50	 

    	 	 	 

    

Company. 
No license or conveyance of any such rights to the Consultant is granted or implied under this Agreement.

 

           
(e)        Assignment.  The Consultant hereby assigns and, to the extent any such
assignment cannot be made at present, hereby agrees to assign to the Company, without further compensation, all of his right,
title and interest in and to all Concepts, Ideas, and Developments. The Consultant will execute all documents and perform all
lawful acts which the Company considers necessary or advisable to secure its rights hereunder and to carry out the intent of this
Agreement.

 

8.        
EQUITABLE RELIEF.  Consultant agrees that any breach of Articles 5 and 6 above by him would cause irreparable damage
to the Company and that, in the event of such breach, the Company shall have, in addition to any and all remedies of law, the
right to seek an injunction, specific performance or other equitable relief to prevent the violation or threatened violation of
Consultant's obligations hereunder.

 

9.        
WAIVER.  Any waiver by the Company of a breach of any provision of this Agreement shall not operate or be construed as
a waiver of any subsequent breach of the same or any other provision hereof.  All waivers by the Company shall be in writing.

 

10.       SEVERABILITY; REFORMATION.  In case any one or more of the provisions or parts of a provision contained in this Agreement
shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability
shall not affect any other provision or part of a provision of this Agreement; and this Agreement shall, to the fullest extent
lawful, be reformed and construed as if such invalid or illegal or unenforceable provision, or part of a provision, had never
been contained herein, and such provision or part reformed so that it would be valid, legal and enforceable to the maximum extent
possible. Without limiting the foregoing, if any provision (or part of provision) contained in this Agreement shall for any reason
be held to be excessively broad as to duration, activity or subject, it shall be construed by limiting and reducing it, so as
to be enforceable to the fullest extent compatible with then existing applicable law.

 

11.      
ASSIGNMENT.  The Company shall have the right to assign its rights and obligations under this Agreement to a party which
assumes the Company' obligations hereunder.  Consultant shall not have the right to assign his rights or obligations under
this Agreement without the prior written consent of the Company.  This Agreement shall be binding upon and inure to the benefit
of the Consultant's heirs and legal representatives in the event of his death or disability.

 

12.      
HEADINGS.  Headings and subheadings are for convenience only and shall not be deemed to be a part of this Agreement.

 

13.      
AMENDMENTS.  This Agreement may be amended or modified, in whole or in part, only by an instrument in writing signed
by all parties hereto. 

 

    	 	51	 

    	 	 	 

    

14.      
NOTICES.  Any notices or other communications required hereunder shall be in writing and shall be deemed given when delivered
in person or when mailed, by certified or registered first class mail, postage prepaid, return receipt requested, addressed to
the parties at their addresses specified in the preamble to this Agreement or to such other addresses of which a party shall have
notified the others in accordance with the provisions of this Section 14.

 

15.      
COUNTERPARTS.  This Agreement may be executed in two or more counterparts, each of which shall constitute an original
and all of which shall be deemed a single agreement.

 

16.      
GOVERNING LAW.  This Agreement shall be construed in accordance with and governed for all purposes by the laws of the
state of New York applicable to contracts executed and wholly performed within such jurisdiction. Any dispute arising hereunder
shall be referred to and heard in only a court located in New York.

 

17.      
SURVIVAL.  The provisions of Sections 6 to 10 and 16 to 17 of this Agreement shall survive the expiration of the Term
or the termination of this Agreement.  This Agreement supersedes all prior agreements, written or oral, between the Company
and the Consultant relating to the subject matter of this Agreement.

 

           
EXECUTED, under seal, effective as of the Effective Date.

 

 

EMBER
THERAPEUTICS, INC. 

 

 

By:
/s/ Joe Hernandez

Joe
Hernandez               

Executive
Chairman

 

 

CONSULTANT

 

 

/s/
Dr. Alexander Mauskop 

Dr. Alexander Mauskop

Hereunto
Duly Authorized  

    	 	52	 

    	 	 	 

    

PATENT
Assignment

This
PATENT ASSIGNMENT, dated as of March [●], 2016 (this “Patent Assignment”), is made by MIGRALEX,
INC., a Delaware corporation (“Seller”), in favor of EMBER THERAPEUTICS, INC., a Delaware
corporation (“Purchaser”), the purchaser of certain assets of Seller pursuant to an Asset Purchase Agreement
between Seller and Purchaser, dated as of March 18, 2016 (the “Purchase Agreement”).

WHEREAS,
under the terms of the Purchase Agreement, Seller has conveyed, transferred and assigned to Purchaser, among other assets, certain
intellectual property of Seller, and has agreed to execute and deliver this Patent Assignment, for recording with governmental
authorities including, but not limited to, the US Patent and Trademark Office.

NOW
THEREFORE, Seller agrees as follows:

1.                 
Assignment. FOR GOOD AND VALUABLE CONSIDERATION, the receipt and sufficiency of which are hereby acknowledged, Seller hereby
irrevocably conveys, transfers and assigns to Purchaser, all of Seller’s right, title and interest in and to the patents,
patent applications (including applications in progress), provisional patents, continuations, divisionals, continuations-in-part
thereof, right to claim priority, extensions and counterparts in the United States and all foreign countries that are listed on
Schedule 1 hereto, (the “Patents”).

2.                 
Recordation. Seller authorizes the Commissioner for Patents and any other governmental officials to record and register
this Patent Assignment upon request by Purchaser.

3.                 
Counterparts. This Patent Assignment may be executed in counterparts, each of which shall be deemed an original, but all
of which together shall be deemed to be one and the same agreement. A signed copy of this Patent Assignment delivered by facsimile,
e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed
copy of this Patent Assignment.

4.                 
Successors and Assigns. This Patent Assignment shall be binding upon and shall inure to the benefit of the parties hereto
and their respective successors and assigns.

5.                 
Governing Law. The provisions hereof shall be governed and interpreted in all respects pursuant to the substantive laws
of the State of New York without regard to its conflict of laws principles.

[signature
page follows]

 

    	 	53	 

    	 	 	 

    

IN
WITNESS WHEREOF, Seller has duly executed and delivered this Patent Assignment to be effective as of the date first above written.

 

MIGRALEX,
INC.

By: /s/ Alexander Mauskop

Name:Alexander Mauskop

Title: President

    	 	54	 

    	 	 	 

    

SCHEDULE
1

Assigned
Patents Registrations And Patent Applications

US
Patent Number 5,538,959, issued July 23, 1996 – expired

US
Patent Number 5,914,129, issued June 22, 1999

    	 	55	 

    	 	 	 

    

Mark
Assignment

This
MARK ASSIGNMENT, dated as of March [●], 2016 (this “Domain Transfer Agreement”), is made
by MIGRALEX, INC., a Delaware corporation (“Seller”), in favor of EMBER THERAPEUTICS, INC.,
a Delaware corporation (“Purchaser”), the purchaser of certain assets of Seller pursuant to an Asset
Purchase Agreement between Seller and Purchaser, dated as of March 18, 2016 (the “Purchase Agreement”).

WHEREAS,
under the terms of the Purchase Agreement, Seller has conveyed, transferred and assigned to Purchaser, among other assets, certain
intellectual property of Seller, and has agreed to execute and deliver this Mark Assignment, for recording with governmental authorities
including, but not limited to, the US Patent and Trademark Office.

NOW
THEREFORE, Seller agrees as follows:

1.                 
Assignment. FOR GOOD AND VALUABLE CONSIDERATION, the receipt and sufficiency of which are hereby acknowledged, Seller hereby
irrevocably conveys, transfers and assigns to Purchaser, all of Seller’s right, title and interest in and to the trademark
registrations and applications set forth in Schedule 1 hereto, together with the goodwill connected with the use of and
symbolized thereby and all issuances, extensions and renewals thereof (the “Marks”), and any and all
claims and causes of action, with respect to any of the foregoing, whether accruing before, on and/or after the date hereof, including
all rights to and claims for damages, restitution and injunctive and other legal and equitable relief for past, present and future
infringement, dilution, misappropriation, violation, misuse, breach or default, with the right but no obligation to sue for such
legal and equitable relief and to collect, or otherwise recover, any such damages.

2.                 
Recordation. Seller authorizes the Commissioner for Trademarks and any other governmental officials to record and register
this Mark Assignment upon request by Purchaser.

3.                 
Counterparts. This Mark Assignment may be executed in counterparts, each of which shall be deemed an original, but all
of which together shall be deemed to be one and the same agreement. A signed copy of this Mark Assignment delivered by facsimile,
e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed
copy of this Mark Assignment.

4.                 
Successors and Assigns. This Mark Assignment shall be binding upon and shall inure to the benefit of the parties hereto
and their respective successors and assigns.

5.                 
Governing Law. The provisions hereof shall be governed and interpreted in all respects pursuant to the substantive laws
of the State of New York without regard to its conflict of laws principles.

[Signature
page follows.]

    	 	56	 

    	 	 	 

    

IN
WITNESS WHEREOF, Seller has duly executed and delivered this Mark Assignment to be effective as of the date first above written.

 

MIGRALEX,
INC.

 

By: /s/ Alexander Mauskop

Name:Alexander Mauskop

Title: President

    	 	57	 

    	 	 	 

    

SCHEDULE
1

Assigned
Trademarks Registrations And Trademark Applications

 

Trademark
DR. MAUSKOP’S MIGRALEX, Reg. No. 4,011,613 Registered Aug. 16, 2011

Trademark
MIGRALEX, Reg. No. 3,781,559 Registered April 27, 2010

Trademark
HEADACHE RELIEF FOR MORE THAN JUST HIS PATIENTS, Reg. No. 3,794,316, Registered May 25, 2010 (expired)

 

Celebrity
endorsements:

Stephanie
Seymour, quotes and photos

Paul
Shaffer quote and photo

 

    	 	58	 

    	 	 	 

    

 

DOMAIN
TRANSFER AGREEMENT

 

This
DOMAIN TRANSFER AGREEMENT, dated as of March [●], 2016 (this “Domain Transfer Agreement”),
is made by MIGRALEX, INC., a Delaware corporation (“Seller”), in favor of EMBER THERAPEUTICS,
INC., a Delaware corporation (“Purchaser”), the purchaser of certain assets of Seller pursuant to
an Asset Purchase Agreement between Seller and Purchaser, dated as of March 18, 2016 (the “Purchase Agreement”).

 

WHEREAS,
under the terms of the Purchase Agreement, Seller is conveying, transferring and assigning to Purchaser, among other assets, certain
intellectual property of Seller, and has agreed to execute and deliver this Domain Transfer Agreement, for transferring the Domain
Names (as defined below) to Purchaser.

NOW
THEREFORE, Seller agrees as follows:

1.                 
Assignment. FOR GOOD AND VALUABLE CONSIDERATION, the receipt and sufficiency of which are hereby acknowledged, Seller hereby
irrevocably conveys, transfers and assigns to Purchaser, all of Seller’s right, title and interest in and to the domain
names listed on Exhibit A attached hereto (collectively, the “Domain Names”):

2.                 
Further Actions with Registrar. Seller agrees to cooperate in all necessary steps to cause the domain name registrar respectively
administering the Domain Names to transfer the Domain Names to Purchaser.

 

3.                 
No Other Rights in Domain Names. Seller represents and warrants that Seller has not registered any other domain name containing
or comprised of MIGRALEX other than the Domain Names.

 

4.                 
Counterparts. This Domain Transfer Agreement may be executed in counterparts, each of which shall be deemed an original,
but all of which together shall be deemed to be one and the same agreement. A signed copy of this Domain Transfer Agreement delivered
by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an
original signed copy of this Domain Transfer Agreement.

 

5.                 
Successors and Assigns. This Domain Transfer Agreement shall be binding upon and shall inure to the benefit of the parties
hereto and their respective successors and assigns.

 

6.                 
Governing Law. The provisions hereof shall be governed and interpreted in all respects pursuant to the substantive laws
of the State of New York without regard to its conflict of laws principles.

 

[Signature
page follows.]

    	 	59	 

    	 	 	 

    

IN
WITNESS WHEREOF, Seller has duly executed and delivered this Domain Transfer Agreement to be effective as of the date first above
written.

 

By: /s/ Alexander Mauskop

Name:Alexander Mauskop

Title: President

 

    	 	60	 

    	 	 	 

    

Domain
Names

buymigralex.com

drmauskopmigralex.com

drmauskopsmigralex.com

drmouskopsmigralex.com

getmigralex.com

magralex.com

magrilex.com

migralax.com

migralex-for-headaches.com

migralex.com

migraplex.com

migrelax.com

migrelex.com

migrilex.com

migrolex.com

mygralex.com

mygrelex.com

mygrilex.com

mygrolex.com

    	 	61Exhibit 4.1

 

FORM OF NOTE

 

STERLING NATIONAL
bank

 

5.25% FIXED-TO-FLOATING
RATE SUBORDINATED NOTEs DUE 2026

 

	 	CUSIP No.	859428 AT1
	 	ISIN No.	US859428AT 18

 

THIS SECURITY IS A GLOBAL SECURITY AND IS REGISTERED IN THE NAME
OF CEDE & CO., THE NOMINEE OF THE DEPOSITORY TRUST COMPANY (THE “DEPOSITARY”). UNLESS AND UNTIL IT IS EXCHANGED
IN WHOLE OR IN PART FOR SECURITIES IN CERTIFICATED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY
TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE
DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY.

 

UNLESS THIS SECURITY IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE
OF THE DEPOSITARY TO STERLING NATIONAL BANK OR ITS AGENT FOR REGISTRATION OF TRANSFER,
EXCHANGE OR PAYMENT, AND ANY SECURITY ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS REQUESTED BY AN
AUTHORIZED REPRESENTATIVE OF THE DEPOSITARY (AND ANY PAYMENT IS MADE TO CEDE & CO. OR SUCH OTHER ENTITY AS IS REQUESTED BY
AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITARY), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON
IS WRONGFUL SINCE THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.

 

THIS SECURITY IS NOT A SAVINGS ACCOUNT OR DEPOSIT AND
IT IS NOT INSURED BY THE FEDERAL DEPOSIT INSURANCE CORPORATION OR ANY AGENCY OR FUND OF THE UNITED STATES.

 

THIS SECURITY IS AN UNSECURED, UNCONDITIONAL GENERAL OBLIGATION
SOLELY OF STERLING NATIONAL BANK AND IS NOT AN OBLIGATION OF, AND IS NOT GUARANTEED BY, STERLING BANCORP OR ANY OTHER AFFILIATE
OF STERLING NATIONAL BANK.

 

THIS SECURITY IS SUBORDINATED ON LIQUIDATION, AS TO PRINCIPAL, INTEREST
AND PREMIUM, TO ALL CLAIMS AGAINST STERLING NATIONAL BANK THAT HAVE THE SAME PRIORITY
AS SAVINGS ACCOUNTS, DEPOSITS OR A HIGHER PRIORITY, IS NOT SECURED BY THE ASSETS OF STERLING
NATIONAL BANK OR BY THE ASSETS OF ANY OF ITS AFFILIATES, AND IS INELIGIBLE AS COLLATERAL TO SECURE A LOAN BY STERLING
NATIONAL BANK.

 

THIS SECURITY IS ISSUABLE IN A MINIMUM DENOMINATION OF $250,000
AND INTEGRAL MULTIPLES OF $1,000 IN EXCESS OF $250,000 AND MAY NOT BE

 

     

     

    

 

EXCHANGED FOR SECURITIES OF STERLING
NATIONAL BANK WITH A SMALLER DENOMINATION. EACH OWNER OF A BENEFICIAL INTEREST
IN THE SECURITIES IS REQUIRED TO HOLD SUCH BENEFICIAL INTEREST IN A PRINCIPAL AMOUNT OF $250,000 OR AN INTEGRAL MULTIPLE OF $1,000
IN EXCESS THEREOF AT ALL TIMES.

 

THIS SECURITY HAS NOT BEEN, AND IS NOT REQUIRED TO BE, REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND WAS OFFERED PURSUANT TO THE EXEMPTION FROM
REGISTRATION PROVIDED BY SECTION 3(a)(2) OF THE SECURITIES ACT. THIS SECURITY
HAS NOT BEEN APPROVED OR DISAPPROVED BY THE BOARD OF GOVERNORS OF THE FEDERAL RESERVE SYSTEM, THE SECURITIES AND EXCHANGE COMMISSION
OR ANY STATE SECURITIES COMMISSION.

 

STERLING NATIONAL BANK
HAS NOT ENTERED INTO AN INDENTURE IN CONNECTION WITH THE ISSUANCE OF THIS SECURITY. EACH PURCHASER OF A BENEFICIAL INTEREST
IN THIS SECURITY, IN MAKING ITS PURCHASE, WILL BE DEEMED TO HAVE REPRESENTED AND WARRANTED TO STERLING NATIONAL BANK AND THE INITIAL
PURCHASERS THAT IT IS AN INSTITUTIONAL INVESTOR THAT IS AN ACCREDITED INVESTOR
AS DEFINED IN REGULATION D UNDER THE SECURITIES ACT (AN “INSTITUTIONAL ACCREDITED INVESTOR”), THAT IT IS PURCHASING
SUCH INTEREST FOR ITS OWN ACCOUNT OR THE ACCOUNT OF ANOTHER INSTITUTIONAL INVESTOR THAT IS AN ACCREDITED INVESTOR AND THAT FOLLOWING
SUCH PURCHASE IT OR SUCH OTHER INSTITUTIONAL ACCREDITED INVESTOR HOLDING A BENEFICIAL INTEREST IN THIS SECURITY WILL HOLD A BENEFICIAL
INTEREST IN A PRINCIPAL AMOUNT OF $250,000 OR AN INTEGRAL MULTIPLE OF $1,000 IN EXCESS THEREOF AT ALL TIMES.

 

	
        

        No. A-1
	 
	INITIAL PRINCIPAL AMOUNT:	$110,000,000
	ORIGINAL ISSUE DATE:	March 29, 2016
	MATURITY DATE:	April 1, 2026
	INTEREST PAYMENT DATE(S):	
        April 1 and October 1, of each year, beginning on October
1, 2016 and ending on April 1, 2021; and thereafter on January 1, April 1, July 1 and October 1, of each year, beginning on July
1, 2021, through the Maturity Date (as defined below) or earlier redemption of the Security 

 

Sterling National Bank, a national banking association (herein called
the “Bank”), for value received, hereby promises to pay or deliver, as the case may be, to CEDE & CO., or registered
assigns, the principal sum of One Hundred Ten Million ($110,000,000) United States dollars on April 1, 2026 (the “Maturity
Date”) and to pay interest thereon from, and including, March 29,

 

    2

     

    

 

2016 (the “Original Issue Date”) or from and including
the most recent Interest Payment Date to which interest on this Security or any predecessor Security has been paid or duly provided
for, but excluding, the succeeding Interest Payment Date, on the Interest Payment Dates specified above in each year (each, an
“Interest Payment Date”) and on the Maturity Date, at a fixed rate per annum equal to 5.25% from the Original Issue
Date to, but excluding, April 1, 2021 and to pay interest from, and including, April 1, 2021 at a floating rate per annum equal
to three-month LIBOR plus 3.937%, until the principal hereof is paid or duly made available for payment (whether at the Maturity
Date or earlier redemption). The interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will
be paid to the person in whose name this Security (or any predecessor Security) is registered (the “Holder”) at the
close of business on the fifteenth calendar day next preceding such Interest Payment Date (the “Regular Record Date”);
provided, however, that interest payable at the Maturity Date of this Security will be payable to the person to whom principal
shall be payable, whether or not the Maturity Date is an Interest Payment Date. Any such interest not so punctually paid or duly
provided for shall forthwith cease to be payable to the Holder on such Regular Record Date and will be paid to the person in whose
name this Security (or any predecessor Security) is registered at the close of business on a special record date for the payment
of such defaulted interest (the “Special Record Date”) to be fixed by the Bank, notice of which shall be given to the
Holder not less than 10 calendar days prior to such Special Record Date.

 

Interest shall accrue from and including the Original Issue Date
or from and including the most recent Interest Payment Date to which interest has been paid or duly provided for, and shall be
paid semi-annually in arrears on April 1 and October 1 of each year, beginning on October 1, 2016, and ending on April 1, 2021,
and thereafter will be payable quarterly in arrears on January 1, April 1, July 1 and October 1 of each year, beginning on July
1, 2021, through the Maturity Date or earlier redemption of this Security. Interest will be computed on the basis of a 360-day
year consisting of twelve 30-day months from the Original Issue Date to, but excluding, April 1, 2021, and thereafter a 360-day
year and the number of days actually elapsed.

 

The Issuing and Paying Agent shall determine LIBOR on the second
Business Day prior to each Interest Period (each such date, a “LIBOR Interest Determination Date”). The interest rate
on this Security bearing interest at the floating rate shall reset on the first day of each Interest Period. Absent manifest error,
the Issuing and Paying Agent’s determination of the floating rate shall be binding and conclusive on the Holder of this Security
and the Bank. The Issuing and Paying Agent shall notify the Bank of each determination of the floating rate for each applicable
Interest Period. “Interest Period” shall be the period from and including the immediately preceding Interest Payment
Date to, but excluding, the succeeding Interest Payment Date. The first Interest Period will be the period from and including the
Original Issue Date to, but excluding, October 1, 2016.

 

LIBOR will be determined as follows:

 

(i)           With respect to each LIBOR Interest Determination
Date, LIBOR will be the ICE Benchmark Administration London Interbank Offered Rate (expressed as a percentage per annum) for deposits
in U.S. dollars for a three-month period beginning on the second London Banking Day after the LIBOR Interest Determination Date
that appears on the appropriate page of the Reuters screen as of 11:00 a.m., London time, on such LIBOR Interest Determination

 

    3

     

    

 

Date. If no such rate so appears, LIBOR on such
LIBOR Interest Determination Date will be determined in accordance with the provision described in clause (ii) below. “London
Banking Day” is any day on which dealings in U.S. dollars are transacted or, with respect to any future date, are expected
to be transacted in the London interbank market.

 

(ii)           If such screen does not include such a rate or is unavailable
on a LIBOR Interest Determination Date, the Issuing and Paying Agent will request the principal London office of each of four major
banks in the London interbank market, as selected by the Issuing and Paying Agent, to provide such bank’s offered quotation
(expressed as a percentage per annum), as of approximately 11:00 a.m., London time, on such LIBOR Interest Determination Date,
to prime banks in the London interbank market for deposits in a principal amount of not less than $1,000,000 for a single transaction
in the relevant market at the relevant time in U.S. dollars for a three-month period beginning on the second London banking day
after the LIBOR Interest Determination Date. If at least two such offered quotations are so provided, the rate for the Interest
Period will be the arithmetic mean of such quotations; provided, however, that if the banks so selected by the Issuing
and Paying Agent are not quoting as mentioned in this sentence, LIBOR determined as of such LIBOR Interest Determination Date shall
be LIBOR in effect on such LIBOR Interest Determination Date.

 

In the event that, on or prior to April 1, 2021, an Interest Payment
Date is not a Business Day (as defined below), the Bank will pay interest on the next day that is a Business Day, with the same
force and effect as if made on the Interest Payment Date, and without any interest or other payment with respect to the delay.
If, after April 1, 2021, any Interest Payment Date falls on a day that is not a Business Day, interest will be paid on the next
succeeding Business Day, unless that day falls in the next calendar month, in which case, the Interest Payment Date will be the
first preceding Business Day (with interest accruing to, but excluding, the actual payment date). If the Maturity Date falls on
a day that is not a Business Day, the payment of principal and interest, if any, will be made on the next succeeding Business Day
and no interest shall accrue for the period from and after such Maturity Date.

 

“Business Day” means any day that is not a Saturday
or Sunday and that is not a day on which banking institutions in New York, New York are generally authorized or obligated by law
or executive order to close.

 

Payment of interest on this Security may require, and be subject
to, prior written approval by the Officer of the Comptroller of the Currency (the “OCC”) or other applicable regulator
of the Bank, if the Bank is undercapitalized or has been so required by the OCC or other applicable regulatory authority.

 

This Security may not be
repaid prior to THE MATURITY DATE, either pursuant to acceleration in an event of default, repurchase by the Bank or otherwise,
without prior approval of the OCC.

 

Payment of principal of and premium, if any, and interest on, this
Security will be made in such coin or currency of the United States of America as at the time of payment is legal tender for payment
of public and private debts. The Bank will at all times appoint and maintain an issuing and paying agent (the “Issuing and
Paying Agent”) authorized by the Bank to pay the principal

 

    4

     

    

 

of, and interest on, this Security on behalf of the Bank and having
an office or agency (the “Issuing and Paying Agent Office”) in the United States of America (the “Place of Payment”),
where this Security may be presented or surrendered for payment and where notices, designations or requests in respect of payments
with respect to this Security may be served. The Bank has initially appointed U.S. Bank National Association as such Issuing and
Paying Agent pursuant to the Issuing and Paying Agency Agreement, dated as of March 29, 2016 (the “Issuing and Paying Agency
Agreement”), between the Bank and the Issuing and Paying Agent, with the Issuing and Paying Agent Office currently located
at 100 Wall Street, Suite 1600, New York, New York 10005, Attention: Global Corporate Trust Services.

 

Payment of the principal of, and premium, if any, and interest on,
this Security due at the Maturity Date will be made in immediately available funds upon presentation and surrender of this Security
to the Issuing and Paying Agent at the Issuing and Paying Agent Office in the Place of Payment; provided that this Security is
presented to the Issuing and Paying Agent in time for the Issuing and Paying Agent to make such payment in accordance with its
normal procedures. Payments of interest on this Security (other than at the Maturity Date) will be made by wire transfer to such
account as has been appropriately designated to the Issuing and Paying Agent by the person entitled to such payments.

 

The Bank may, from time to time, without the consent of the Holder
of this Security, create and issue additional notes ranking equally with this Security and otherwise same in all respects (except
for the issue date, issue price and first Interest Payment Date), provided that any such additional notes are fungible with the
Securities for U.S. Federal income tax purposes. Such further notes shall be consolidated and form a single series (including the
same CUSIP number) with this Security.

 

Reference is hereby made to the further provisions of this Security
set forth on the reverse hereof, which further provisions shall for all purposes have the same effect as if set forth at this place.

 

(Remainder of page intentionally left blank)

 

    5

     

    

 

Unless the certificate of authentication hereon has been executed
by the Issuing and Paying Agent by the manual signature of an authorized signatory, this Security shall not be valid or obligatory
for any purpose.

 

IN WITNESS WHEREOF, the Bank has caused this instrument to be duly
executed by manual or facsimile signature.

 

	 	STERLING NATIONAL BANK
	 	 	 
	 	By:	 
	 	Name:	Jack Kopnisky
	 	Title:	President & Chief Executive Officer

 

Dated: March 29, 2016

 

ISSUING AND PAYING AGENT’S CERTIFICATE OF AUTHENTICATION

 

This is one of the Securities referred to in the within-mentioned
Issuing and Paying Agency Agreement.

 

U.S. BANK NATIONAL ASSOCIATION, as Issuing and Paying Agent

 

	By: 	 	 
	 	Authorized Signatory	 

 

 

     

     

    

 

REVERSE OF SECURITY

 

This Security is one of a duly authorized issue of 5.25% Fixed-to-Floating
Rate Subordinated Notes due 2026 of the Bank (hereinafter referred to as this “Security” or the “Securities”)
issued under the Issuing and Paying Agency Agreement.

 

Subordination

 

The Bank’s indebtedness evidenced by this Security, including
its obligations to pay principal and interest, is unsecured and subordinate and junior in right of payment to the Bank’s
Senior Indebtedness (as defined below). In the event of any insolvency, receivership, conservatorship, reorganization, liquidation
or similar proceedings of the Bank, all such senior obligations shall be entitled to be paid in full before any payment shall be
made on account of the principal of, or premium, if any, or interest on, this Security. In the event of any such proceeding, after
payment in full of all sums owing with respect to such senior obligations, the Holder of this Security, together with holders of
any obligations of the Bank ranking equally with this Security, shall be entitled to be paid from the remaining assets of the Bank
the unpaid principal of, premium, if any, and interest on, this Security or such other obligations before any payment or other
distribution, whether in cash, property, or otherwise, shall be made on account of any capital stock or any obligations of the
Bank ranking junior to this Security.

 

“Senior Indebtedness” includes all deposits, borrowed
money (secured and unsecured), obligations of the Bank arising from off-balance sheet guarantees and direct-credit substitutes,
and obligations associated with derivative products such as interest rate and foreign-exchange contracts, commodity contracts and
similar arrangements and obligations to the Bank’s general creditors (other than in respect of trade receivables).

 

Nothing herein shall impair the obligation of the Bank, which is
absolute and unconditional, to pay the principal of, and premium, if any, and interest on this Security in accordance with its
terms.

 

Notwithstanding any other provisions contained in this Security,
the OCC or any receiver or conservator of the Bank appointed by the OCC, as part of any transaction or plan of reorganization or
liquidation may transfer or direct the transfer of the obligations represented by this Security to any bank selected by such entity
that expressly assumes the obligation of the due and punctual payment of the unpaid principal, premium, if any, and interest on
this Security and the due and punctual performance of all covenants and conditions contained in this Security.

 

Any “depository institution,” as that term is defined
in Section 3(c)(1) of the Federal Deposit Insurance Act, which holds a Security (or beneficial interest therein) shall be deemed
to have agreed by acquiring such Security (or beneficial interest) to waive any rights to offset all or any portion of the indebtedness
represented by such Security (or interest) against any indebtedness or other obligations of such institution to the Bank.

 

This Security is not secured or guaranteed by Sterling Bancorp or
any of its other subsidiaries or affiliates, and is not subject to any other arrangement that legally or economically enhances
the seniority of this Security.

 

    	R-1

     

    

 

Event of Default; Waiver

 

An “Event of Default” with respect to this Security
shall occur if the Bank is subject to any receivership, conservatorship, insolvency, liquidation or similar proceeding. The Bank
will promptly notify, and provide copies of such notice to, the Issuing and Paying Agent, upon the occurrence of any Event of Default.
The Issuing and Paying Agent will promptly send copies of such notice to the Holders of this Security through the Depository Trust
Company, as depositary (the “Depositary”).

 

If an Event of Default shall occur and be continuing, the Holder
of this Security may declare the principal of this Security, together with any unpaid accrued interest thereon, to be immediately
due and payable by written notice to the Bank. Upon such declaration and notice, such principal amount and accrued interest shall
become immediately due and payable; provided, however, that, to the extent then required under or pursuant to applicable
capital or other regulations (as described on the face of this Security), this Security may not be repaid prior to the Maturity
Date without the prior written approval of the OCC. The Bank will apply to the OCC for prior written approval of repayment promptly
after receiving notice of acceleration.

 

Any Event of Default with respect to this Security may be waived
by the Holder hereof.

 

The Bank waives demand, presentment for prepayment, notice of nonpayment,
notice of protest and all other notices to the extent it may lawfully do so.

 

Neither the failure to pay principal of or interest on the Security
nor a failure to perform any other obligation of the Bank under the Issuing and Paying Agency Agreement or the Security constitutes
an “Event of Default” with respect to the Security, and no right of acceleration exists in any such case.

 

Optional Repayment and Redemption

 

This Security shall not be subject to repayment at the option of
the Holders, in whole or in part, prior to the Maturity Date. This Security shall not be subject to any sinking fund.

 

This Security is redeemable by the Bank, in whole or in part, at
any time on April 1, 2021, and on each Interest Payment Date thereafter.

 

This Security is also redeemable by the Bank, in whole but not in
part, at any time, upon the occurrence of any of the following:

 

		(i)	a “tax event,” which means the receipt by the Bank of an opinion of independent tax counsel to the effect that
(a) an amendment to or change (including any announced prospective amendment or change) in any law or treaty, or any regulation
thereunder, of the United States or any of its political subdivisions or taxing authorities, (b) a judicial decision, administrative
action, official administrative pronouncement, ruling, regulatory procedure, regulation, notice or announcement, including any
notice or announcement of intent to adopt or promulgate any ruling, regulatory procedure or regulation, (c) an amendment to or
change in any official position with respect to, or any interpretation of, an administrative or judicial action or a law or regulation
of the United States that differs

 

    	R-2

     

    

 

from the previously generally accepted position or interpretation,
or (d) a threatened challenge asserted in writing in connection with an audit of the Bank’s federal income tax returns or
positions or a similar audit of any of the Bank’s subsidiaries or a publicly known threatened challenge asserted in writing
against any other taxpayer that has raised capital through the issuance of securities that are substantially similar to this Security,
in each case, occurring or becoming publicly known on or after the date of the issuance of this Security, resulting in more than
an insubstantial risk that the interest payable on this Security is not, or within 90 days of receipt of such opinion of tax counsel,
will not be, deductible by the Bank, in whole or in part, for U.S. federal income tax purposes;

 

		(ii)	a “capital event,” which means the receipt by the Bank of an opinion of independent bank regulatory counsel to
the effect that, as a result of (a) any amendment to, or change (including any announced prospective change) in, the laws or any
regulations thereunder of the United States or any rules, guidelines or policies of an applicable regulatory authority for Sterling
Bancorp or the Bank or (b) any official administrative pronouncement or judicial decision interpreting or applying such laws or
regulations, which amendment or change is effective or which pronouncement or decision is announced on or after the date of original
issuance of this Security, this Security does not constitute, or within 90 days of the date of such opinion will not constitute,
Tier 2 capital (or its then equivalent if the Bank is subject to such capital requirement) for purposes of capital adequacy guidelines
of the OCC (or any successor regulatory authority with jurisdiction over depositary institutions or bank holding companies), as
then in effect and applicable to the Bank; or

 

		(iii)	an “investment company event,” which means the Bank becoming required to register as an investment company pursuant
to the Investment Company Act of 1940, as amended.

 

Any such redemption of this Security will be at a redemption price
equal to 100% of the principal amount of this Security to be redeemed, plus accrued and unpaid interest on such Security to, but
excluding, the date of redemption. Any partial redemption will be made pro rata among all of the holders of this Security. Any
redemption of this Security would require prior written approval of the OCC.

 

The Bank will give irrevocable notice of its intention to redeem
this Security not more than 60 nor less than 10 days prior to the date fixed for redemption.

 

From and after any redemption date, if monies for the redemption
of this Security will have been made available for redemption on the redemption date, this Security will cease to bear interest,
if applicable, and the only right of the holders of this Security shall be to receive payment of the principal amount and all unpaid
interest accrued to the redemption date.

 

Consolidation, Merger and Sale of Assets 

 

The Bank shall not consolidate with or merge into any other entity
or convey, transfer or lease its assets substantially as an entirety to any entity, unless the successor, transferee or lessor
expressly assumes the Bank’s obligations on this Security.

 

    	R-3

     

    

 

Ratings

 

The Bank shall use commercially reasonable efforts to maintain a
rating for this Security with NAIC or any other “nationally recognized statistical rating organization” as defined
in Section 3(a)(62) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

 

Miscellaneous

 

Beneficial interests represented by this Security are exchangeable
for definitive Securities in registered form, of like tenor and of an equal aggregate principal amount, only if (x) the Depositary
notifies the Bank in writing that it is unwilling or unable to act as a depositary or the Depositary ceases to be a clearing agency
registered under the Exchange Act, and a successor depositary is not appointed by the Bank within 90 days, (y) the Bank, at its
option, notifies the Issuing and Paying Agent in writing that it elects to cause the issuance of Securities in definitive form
or (z) any event shall have occurred and be continuing that, after notice or lapse of time or both, would constitute an Event
of Default with respect to the this Security. In such circumstances, upon surrender by the Depositary or a successor depositary
of the Global Securities, Securities in definitive form will be issued to each person that the Depositary or a successor depositary
identifies as the beneficial owner of the related Securities. Any Security representing such beneficial interests that is exchangeable
pursuant to this paragraph shall be exchangeable in whole for definitive Securities in registered form, of like tenor and of an
equal aggregate principal amount, in minimum denominations of $250,000 and integral multiples of $1,000 in excess thereof. Such
definitive Securities shall be registered in the name or names of such person or persons as the Depositary shall instruct the Security
Registrar (as defined below).

 

In case any Security shall at any time become mutilated, destroyed,
lost or stolen and such Security or evidence satisfactory to the Bank of the loss, theft or destruction thereof (together with
indemnity satisfactory to the Issuing and Paying Agent and the Bank and such other documents or proof as may be required by the
Issuing and Paying Agent and the Bank) shall be delivered to the Issuing and Paying Agent and the Bank, a new Security of like
tenor will be issued by the Bank in exchange for the Security so mutilated, or in lieu of the Security so destroyed or lost or
stolen. All expenses and reasonable charges associated with procuring the indemnity referred to above and with the preparation,
authentication and delivery of a new Security shall be borne by the Holder of the Security so mutilated, destroyed, lost or stolen.
If any Security which has matured or is about to mature shall become mutilated, destroyed, lost or stolen, the Bank may, instead
of issuing a substitute Security, pay or authorize the payment of the same (without surrender thereof except in the case of a mutilated
Security) upon compliance by the Holder thereof with the provisions of this paragraph.

 

The Bank shall cause to be kept at the office of the Security Registrar
designated below a register (the register maintained in such office or any other office or agency of the Bank in the Place of Payment
herein referred to as the “Security Register”) in such form as the Security Registrar may determine, in which, subject
to reasonable regulations as it may prescribe, the Security Registrar shall provide for the registration of this Security and of
transfers of this Security. The Bank has initially appointed the Issuing and Paying Agent “Security Registrar,” pursuant
to the Issuing and Paying Agency Agreement, for the purposes of registering this Security and transfers of this Security as herein
provided.

 

    	R-4

     

    

 

The transfer of this Security is registrable in the Security Register,
upon surrender of this Security for registration of transfer at the office or agency of the Bank in the Place of Payment, duly
endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Bank and the Issuing and Paying Agent
duly executed by, the Holder hereof or his attorney duly authorized in writing, and thereupon one or more new Securities of like
tenor, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or
transferees.

 

No service charge shall be made for any such registration of transfer
or exchange, but the Bank may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection
therewith.

 

The Issuing and Paying Agent shall record any transfer of this Security
that the Bank has approved, it being understood that such approval shall be based solely on matters relating to compliance with
federal and state securities laws. Prior to due presentment of this Security for registration of transfer, the Bank, the Issuing
and Paying Agent and any agent of the Bank or the Issuing and Paying Agent may treat the person in whose name this Security is
registered as the owner hereof for all purposes, whether or not this Security is overdue, and neither the Bank, the Issuing and
Paying Agent nor any such agent shall be affected by notice to the contrary.

 

No recourse shall be had for the payment of principal or interest
on this Security, for any claim based hereon, or otherwise in respect hereof, against any shareholder, employee, agent, officer
or director, as such, past, present or future, of the Bank or any successor corporation.

 

No provision of this Security shall alter or impair the obligation
of the Bank, which is absolute and unconditional, to pay the principal of and interest on this Security at the times, place and
rate, and in the coin or currency, herein prescribed.

 

Any money that the Bank pays to the Issuing and Paying Agent for
the purpose of making payments on this Security and that remains unclaimed two years after the payments were due will, at the Bank’s
request, be returned to it. After that time, the Holder can only look to the Bank for payment on this Security.

 

All notices under this Security shall be in writing and in the case
of the Bank, addressed to the Bank at 400 Rella Boulevard, Montebello, New York 10901, Attention: Treasurer, or, in the case of
the Issuing and Paying Agent at 100 Wall Street, Suite 1600, New York, New York 10005, Attention: Global Corporate Trust Services,
or to such other address of the Issuing and Paying Agent as the Issuing and Paying Agent may notify the holders of this Security.
All notices to the Holder of this Security will be given to the address of the Holder as it appears in the Security Register.

 

This Security shall be governed by and construed in accordance
with the laws of the State of New York and, where applicable, the federal laws of the United States of America.

 

    	R-5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}]]